Cosmos Health (COSM) S-1/A 22 Jan 18 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2017
Document And Entity Information
Entity Registrant Name	Cosmos Holdings Inc.
Entity Central Index Key	1,474,167
Document Type	S1
Document Period End Date	Sep. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Document Fiscal Year Focus	2,017

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 1,352,172	$ 716,590	$ 198,049
Accounts receivable	2,858,518	661,850	96,544
Other receivable		131,900
Inventory	2,096,818	464,219	191,874
Prepaid deferred financing fees	361,289
Prepaid expenses and other current assets	2,904,989	646,530	60,709
Prepaid expenses and other current assets - related party	481,450	15,523
TOTAL CURRENT ASSETS	10,055,236	2,636,612	547,176
Other assets	656,382	429,203	59,916
Property and equipment, net	79,521	52,715	50,529
Intangible assets, net	44,012
TOTAL ASSETS	10,835,151	3,118,530	657,621
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,338,047	577,932	196,420
Accounts payable and accrued expenses - related party	981	13,759	140,513
Deferred revenue			62,210
Notes payable, net of unamortized discount of $154,949 and $110,561, respectively	9,274,201	2,872,472	109,060
Notes payable - related party	116,358	160,391	283,831
Loans payable		17,938	32,718
Loans payable - related party	559,557	148,250	48,532
Taxes payable	1,313,030	1,080,590	1,032,128
TOTAL CURRENT LIABILITIES	13,602,174	4,871,332	1,905,412
TOTAL LIABILITIES	13,602,174	4,871,332	1,905,412
Commitments and Contingencies (see Note 9)
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value; 100,000,000 shares authorized; 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively
Common stock, $0.001 par value; 300,000,000 shares authorized; 12,825,393 and 12,587,053 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	12,825	12,587	12,563
Additional paid-in capital	2,525,164	287,293	246,541
Accumulated other comprehensive loss	(1,228,614)	(1,050,463)	(1,105,678)
Accumulated deficit	(4,076,398)	(1,002,219)	(401,217)
TOTAL STOCKHOLDERS' DEFICIT	(2,767,023)	(1,752,802)	(1,247,791)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 10,835,151	$ 3,118,530	$ 657,621

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
CURRENT LIABILITIES:
Notes payable, net of unamortized discount	$ 154,949	$ 110,561	$ 0
SHAREHOLDERS' EQUITY
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000	100,000,000
Preferred stock, shares issued	0	0	0
Preferred stock, shares, outstanding	0	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000	300,000,000
Common stock, shares issued	12,825,393	12,587,053	12,563,053
Common stock, shares, outstanding	12,825,393	12,587,053	12,563,053

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
REVENUE
Revenue	$ 9,546,951	$ 1,414,503	$ 19,775,398	$ 3,506,804	$ 6,755,436	$ 533,802
COST OF REVENUE	8,772,138	1,269,553	18,156,795	3,192,472	6,154,396	484,809
GROSS PROFIT	774,813	144,950	1,618,603	314,332	601,040	48,993
OPERATING EXPENSES
General and administrative expenses	752,198	173,498	2,416,540	466,293	794,099	486,036
Depreciation and amortization expense	6,167	2,421	17,199	6,956	9,448	5,416
Impairment of goodwill			1,949,884
TOTAL OPERATING EXPENSES	758,365	175,919	4,383,623	473,249	803,547	491,452
GAIN (LOSS) FROM OPERATIONS	16,448	(30,969)	(2,765,020)	(158,917)	(202,507)	(442,459)
OTHER INCOME (EXPENSE)
Interest income						1,063
Other income				19	19	814
Interest expense - related party	(66)	(919)	(198)	(2,741)	(264)	(3,481)
Interest expense	(291,224)	(53,794)	(572,679)	(103,803)	(205,750)	(86,898)
Other expense	(13,295)	(3,388)	(26,529)	(4,539)	(12,764)	(6,000)
Write off on investment of B2IN						(6,150,508)
Foreign currency transaction gain (loss)	89,966	(5,555)	292,937	(7,043)	(178,967)	(240)
TOTAL OTHER INCOME (EXPENSE)	(214,619)	(63,656)	(306,469)	(118,107)	(397,726)	(6,245,250)
LOSS BEFORE INCOME TAXES	(198,171)	(94,625)	(3,071,489)	(277,024)	(600,233)	(6,687,709)
INCOME TAX EXPENSE		12	(2,690)	(773)	(769)	(203)
NET LOSS	(198,171)	(94,613)	(3,074,179)	(277,797)	(601,002)	(6,687,912)
OTHER COMPREHENSIVE LOSS
Foreign currency translation loss	(51,474)	(16,622)	(178,151)	(38,185)	55,215	(424,713)
TOTAL OTHER COMPREHENSIVE LOSS	$ (249,645)	$ (111,235)	$ (3,252,330)	$ (315,982)	$ (545,787)	$ (7,112,625)
BASIC AND DILUTED NET LOSS PER SHARE	$ (0.02)	$ (0.01)	$ (0.24)	$ (0.02)	$ (0.05)	$ (0.53)
DILUTED NET LOSS PER SHARE					$ (0.05)	$ (0.53)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING
Basic and Diluted	12,823,622	12,563,053	12,764,720	12,563,053
BASIC WEIGHTED AVERAGE SHARES OUTSTANDING					12,564,824	12,561,598
DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING					12,564,824	12,561,598

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings Deficit	Accumulated Other Comprehensive Loss	Total
Beginning Balance, Shares at Dec. 31, 2014		12,558,553
Beginning Balance, Amount at Dec. 31, 2014		$ 12,559	$ (144,666)	$ 6,286,695	$ (680,965)	$ 5,473,623
Foreign currency translation effect					(424,713)	(424,713)
Related party forgiveness of debt			362,859			362,859
Issuance of common stock for consulting services, Shares		4,500
Issuance of common stock for consulting services, Value		$ 4	28,348			28,352
Net income				(6,687,912)		(6,687,912)
Ending Balance, Shares at Dec. 31, 2015		12,563,053
Ending Balance, Amount at Dec. 31, 2015		$ 12,563	246,541	(401,217)	(1,105,678)	(1,247,791)
Foreign currency translation effect					55,215	55,215
Related party forgiveness of debt						362,859
Issuance of common stock for consulting services, Value						28,352
Issuance of common stock for the exercise of options, Shares		24,000
Issuance of common stock for the exercise of options, Amount		$ 24	23,976			24,000
Stock option expense			16,636			16,636
Contribution of capital by an officer				140		140
Net income				(601,002)		(601,002)
Ending Balance, Shares at Dec. 31, 2016		12,587,053
Ending Balance, Amount at Dec. 31, 2016		$ 12,587	$ 287,293	$ (1,002,219)	$ (1,050,463)	(1,752,802)
Net income						(3,074,179)
Ending Balance, Amount at Sep. 30, 2017						$ (2,767,023)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,074,179)	$ (277,797)	$ (601,002)	$ (6,687,912)
Adjustments to Reconcile Net Loss to Net Cash Used In Operating Activities:
Depreciation and amortization expense	17,199	6,956	9,448	5,416
Amortization of debt discount	87,677	5,885	16,063
Stock-based compensation	265,529		16,636	28,352
Write off of investment in B2IN				6,150,508
Issuance of common stock for services	401,800
Loss on goodwill impairment	1,949,884
Changes in Assets and Liabilities:
Accounts receivable	(2,137,831)	(316,012)	(565,306)	(96,544)
Inventory	(1,627,085)	(189,435)	(272,345)	(191,874)
Prepaid expenses	(2,242,785)	(198,627)	(585,821)	(28,209)
Prepaid expenses - related party	(465,927)	(119,796)	(15,523)
Other assets	(166,896)	(55,880)	(369,287)	(28,503)
Accounts payable and accrued expenses	1,056,165	70,681	381,512	53,169
Accounts payable and accrued expenses - related party	(12,778)	(135,117)	(126,754)	140,513
Taxes payable	209,667	36,331	48,508	95,785
Deferred revenue		(62,210)	(62,210)	62,210
NET CASH USED IN OPERATING ACTIVITIES	(5,739,560)	(1,235,021)	(2,126,081)	(497,089)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(13,925)	(11,880)	(12,816)
Payment of financing management fee			(131,900)	(43,952)
Cash received from acquisition	40,858
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	26,933	(11,880)	(144,716)	(43,952)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of related party note payable	(63,200)	(44,952)	(63,312)	163,624
Payment of note payable	(461,888)	(148,904)	(176,218)
Proceeds from note payable	6,891,203	1,968,940	2,871,993	87,248
Payment of related party loan	(232,051)	(21,914)	(15,300)	(3,000)
Proceeds from related party loan	625,641	51,127	148,250	48,532
Proceeds from loan payable				32,718
Payment of loans payable	(20,082)	(33,714)	(45,374)
Sale of common stock and warrants	91,780
Deferred financing fees	(213,626)	(140,475)
Proceeds from the exercise of stock options			24,000
Capital contribution		140	140
NET CASH PROVIDED BY FINANCING ACTIVITIES	6,617,777	1,630,248	2,744,179	329,122
Effect of exchange rate changes on cash	(269,568)	38,377	45,159	(36,636)
NET INCREASE IN CASH	635,582	421,724	518,541	(248,555)
CASH AT BEGINNING OF PERIOD	716,590	198,049	198,049	446,604
CASH AT END OF PERIOD	1,352,172	619,773	716,590	198,049
Supplemental Disclosure of Cash Flow Information
Cash paid during the period: Interest	127,157		30,396
Cash paid during the period: Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Acquisition of Decahedron	1,479,000
Reversal of proceeds due from noteholder due to repayment of note	$ 11,813
Note payable issued for payment of accounts payable				22,202
Proceeds receivable from issuance of loan agreement				21,812
Forgiveness of debt by related party				$ 362,859

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
NOTE 1- BASIS OF PRESENTATION	The terms “COSM,” “we,” “the Company,” and “us” as used in this report refer to Cosmos Holdings Inc. The accompanying unaudited consolidated balance sheet as of September 30, 2017 and unaudited consolidated statements of operations for the three and nine months ended September 30, 2017 have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management of COSM, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the nine months ended September 30, 2017, are not necessarily indicative of the results that may be expected for the year ending December 31, 2017, or any other period. These unaudited consolidated financial statements and notes should be read in conjunction with the financial statements for each of the two years ended December 31, 2016 and 2015, included in the Company’s Annual Report on Form 10-K. The accompanying consolidated balance sheet as of December 31, 2016 has been derived from the audited financial statements filed in our Form 10-K and is included for comparison purposes in the accompanying balance sheet. Certain prior year amounts have been reclassified to conform to current year presentation.

ORGANIZATION, NATURE OF BUSINES

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 2 - ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN	Cosmos Holdings, Inc. (“Cosmos”, “The Company”, “we”, or “us”) was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009 for the purpose of acquiring and operating commercial real estate and real estate related assets. On September 27, 2013 (the “Closing”), Cosmos Holding Inc. a Nevada corporation (“Cosmos Holdings, Inc.” or the “Registrant”), closed a reverse take-over transaction by which it acquired a private company whose principal activities are the trading of products, providing representation, and provision of consulting services to various sectors. Pursuant to a Share Exchange Agreement (the “Exchange Agreement”) between the Registrant and Amplerissimo Ltd, a company incorporated in Cyprus (“Amplerissimo”), the Registrant acquired 100% of Amplerissimo’s issued and outstanding common stock. On August 1, 2014, we, through our Cypriot subsidiary Amplerissimo, formed SkyPharm S.A. a Greek corporation (“SkyPharm”) whose principal activities and operations are the development, marketing and sales of pharmaceutical, wellness and cosmetic products. On February 10, 2017, the Company and Decahedron Ltd, a UK Corporation (“Decahedron”) consummated the transactions contemplated by the Stock Purchase Agreement, dated November 17, 2016 as amended (the “Decahedron SPA”). Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 1,700,000 shares of common stock of the Company (the “Stock Consideration”), which were delivered following the closing in exchange for all of the Ordinary Shares of Decahedron for the Stock Consideration. In accordance with the terms of the SPA, Mr. Lazarou remained as a director and officer of Decahedron. On November 21, 2017, the Company effected a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of retroactively issued and outstanding shares of Common Stock. Proportional adjustments for the reverse stock split were made to the Company’s outstanding stock options, warrants and equity incentive plans, including all share and per-share data, for all amounts and periods presented in the consolidated financial statements. We are currently focusing our existing operations on expanding the business of SkyPharm and our new subsidiary Decahedron, we have concentrated our efforts on becoming an international pharmaceutical company. The Company’s focus will be on Branded Pharmaceuticals, Over-the-Counter (OTC) medicines, and Generic Pharmaceuticals. The Company also intends to expand into Cosmetic-Beauty Products as well as Food Supplements and we target areas where we can build and maintain a strong position. The Company uses a differentiated operating model based on a lean, nimble and decentralized structure, an emphasis on low risk license acquisition as well as Research & Development and our ability to be better owners of pharmaceutical assets than others. This operating model and the execution of our corporate strategy are enabling the Company to achieve sustainable growth and create shareholder value. We regularly evaluate and, where appropriate, execute on opportunities to expand through the acquisition of branded pharmaceutical products and pharmaceutical companies in areas that will serve patients that we believe will offer above average growth characteristics and attractive margins. In particular, we look to continue to enhance our pharmaceutical and over the counter product lines by acquiring or licensing rights to additional products and regularly evaluate selective acquisition opportunities. Going Concern The Company’s consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company generated a net loss of $3,074,179 for the nine months ended September 30, 2017, and has a working capital deficit of $3,546,938 and an accumulated deficit of $4,076,398 as of September 30, 2017. These conditions raise substantial doubt of the Company’s ability to continue as a going concern. The Company has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management’s plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd, SkyPharm S.A. and Decahedron Ltd. All significant intercompany balances and transactions have been eliminated. Reclassifications to Prior Period Financial Statements and Adjustments Certain reclassifications have been made in the Company’s financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2017 and December 31, 2016, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom of Great Britain, dominated in Euros and Great Britain Pound (British Pounds Sterling). Account Receivable Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Inventory Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5-7 years Office and computer equipment 3-5 years Depreciation expense was $10,831 and $6,956 for the nine months ended September 30, 2017 and 2016, respectively. Intangible Assets Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At September 30, 2017, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $6,368 and $0 for the nine months ended September 30, 2017 and 2016, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Goodwill and Intangibles The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no record goodwill value. As a result of the acquisition of Decahedron, the Company tested and expensed 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the period ending September 30, 2017. Fair Value Measurement The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of September 30, 2017. Cash is considered to be highly liquid and easily tradable as of September 30, 2017 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Revenue Recognition We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided. Stock-based Compensation The Company records stock based compensation in accordance with ASC section 718, “Stock Compensation” and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees”. Foreign Currency Translations and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net earnings. Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus, Greece and the United Kingdom of England. The corporate income tax rate in Cyprus is 12.5%, 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At September 30, 2017 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management’s judgment, the position is not more-likely-then-not sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of September 30, 2017 the Company has no uncertain tax positions recorded in any jurisdiction where it is subject to income tax. Basic and Diluted Net Income (Loss) per Common Share Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in periods with net income. Basic and diluted loss per share for each of the periods ended September 30, 2017 and 2016 is the same due to the anti-dilutive nature of potential common stock equivalents. Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The Company does not believe that the adoption of ASU No. 2017-4 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition of assets or a business. ASU No. 2017-01 is effective for the Company’s fiscal year commencing on January 1, 2018. The effect of this guidance is to be applied prospectively and early adoption is permitted. The Company does not believe that the adoption of ASU No. 2017-01 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require lessees to recognize assets and liabilities for the rights and obligations created by most leases on the balance sheet. The changes become effective for the Company’s fiscal year beginning July 1, 2019. Modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, is required with an option to use certain transition relief. The Company expects this ASU will increase its current assets and current liabilities, but have no net material impact on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09--Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	Cosmos Holdings, Inc. ("Cosmos", "The Company", "we", or "us") was incorporated in the State of Nevada under the name Prime Estates and Developments, Inc. on July 21, 2009 for the purpose of acquiring and operating commercial real estate and real estate related assets. On September 27, 2013 (the "Closing"), Cosmos Holdings, Inc. a Nevada corporation ("Cosmos Holdings, Inc." or the "Registrant"), closed a reverse take-over transaction by which it acquired a private company whose principal activities are the trading of products, providing representation, and provision of consulting services to various sectors. Pursuant to a Share Exchange Agreement (the "Exchange Agreement") between the Registrant and Amplerissimo Ltd, a company incorporated in Cyprus ("Amplerissimo"), the Registrant acquired 100% of Amplerissimo's issued and outstanding common stock. On August 1, 2014, we, through our Cypriot subsidiary Amplerissimo, formed SkyPharm S.A. a Greek Corporation ("SkyPharm") whose principal activities and operations are the development, marketing and sales of pharmaceutical and cosmetic products. The Company had $6,755,436 total revenues and expended approximately $6,957,943 for the year ended December 31, 2016, in connection with these operations. Going Concern The Company's consolidated financial statements are prepared using U.S. GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company generated a net loss of $601,002 for the year ended December 31, 2016, and has a working capital deficit of $2,234,720 and an accumulated deficit of $1,002,219 as of December 31, 2016. These conditions raise substantial doubt of the Company’s ability to continue as a going concern. The Company has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. If the Company is unable to obtain adequate capital, it could be forced to cease development of operations. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Summary of Significant Accounting Policies Basis of Financial Statement Presentation The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America. Principles of Consolidation Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd and SkyPharm S.A. All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2016 and December 31, 2015, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. For the year ended December 31, 2016, the amounts in these accounts were $3,143 and $19,876 (the Euro equivalent of which was €18,836). At December 31, 2015, the amounts in these accounts were $(190) and $7,808 (the Euro equivalent of which was €7,159). Account Receivable Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information. Inventory Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. Fixed Assets Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years Depreciation expense was $9,448 and $5,416 for the years ended December 31, 2016 and December 31, 2015, respectively. Impairment of Long-Lived Assets In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Fair Value Measurement The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2016. Cash is considered to be highly liquid and easily tradable as of December 31, 2016 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments. Revenue Recognition We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided. Stock-based Compensation The Company records stock based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees". Foreign Currency Translations and Transactions Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2016 2015 Number of 10% clients 2 2 Percentage of total revenue 52.49 % 87.21 % Percentage of total AR 26.09 % 46.97 % Income Taxes The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus and Greece. The corporate income tax rate in Cyprus is 12.5% and 29% in Greece and tax losses are carried forward for five years effective January 1, 2013 (prior to 2013, losses were carried forward indefinitely). Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2016 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management's judgment, the position is not more-likely-then-not sustainable upon audit based on the position's technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of December 31, 2016 the Company has no uncertain tax positions recorded in any jurisdiction where it is subject to income tax. Basic and Diluted Net Income (Loss) per Common Share Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in years with net income. Basic and diluted loss per share for each of the years ended December 31, 2015 and 2016 is the same due to the anti-dilutive nature of potential common stock equivalents. Recent Accounting Pronouncements In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of the revenue standard issued in 2014, ASU 2014-09, Revenue from Contracts with Customers. In response to stakeholders' requests to defer the effective date of the guidance in ASU 2014-09 and in consideration of feedback received through extensive outreach with preparers, practitioners, and users of financial statements, the FASB proposed deferring the effective date of ASU 2014-09. Respondents to the proposal overwhelmingly supported a deferral. Respondents noted that providing sufficient time for implementation of the guidance in ASU 2014-09 is critical to its success. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which requires that an entity classify deferred tax assets and liabilities as noncurrent on the balance sheet. Prior to the issuance of the standard, deferred tax assets and liabilities were required to be separated into current and noncurrent amounts on the basis of the classification of the related asset or liability. This ASU is effective for the Company on April 1, 2017, with early adoption permitted. The adoption of ASU No. 2015-17 is not expected to have a material impact on the Company's condensed consolidated financial statements or related disclosures. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.

LOAN RECEIVABLE

LOAN RECEIVABLE	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 2 - LOAN RECEIVABLE	On February 28, 2016, the Company entered into an agreement with Synthesis Management Limited (“Synthesis Management”) to loan €125,000 ($131,900) to Synthesis Management for the purpose of paying a financing management fee. The Company made the payment to Synthesis Management on September 28, 2016. The loan is non-interest bearing and has a maturity date of December 31, 2016. As of the date of filing, the Company has agreed to extend the maturity date of the loan until December 31, 2017, however no formal written amendment has been delivered.

ACQUISITION OF DECAHEDRON, LTD.

ACQUISITION OF DECAHEDRON, LTD.	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
NOTE 3- ACQUISITION OF DECAHEDRON, LTD.	On February 10, 2017, the Company completed the acquisition pursuant to the Decahedron SPA acquiring 100% of the outstanding shares of Decahedron, a United Kingdom company. Decahedron is a pharmaceuticals wholesaler which specializes in imports and exports of branded and generic pharmaceutical products within the EEA and around the world. At closing, the Company acquired 100% of Decahedron’s outstanding shares in exchange for 170,000 shares of Cosmos common stock valued at $1,479,000 (the “Acquisition”). The Company recognized the Decahedron assets acquired and liabilities assumed based upon the fair value of such assets and liabilities measured as of the date of acquisition. The aggregate purchase price for Decahedron has been allocated to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The excess of the purchase price over the fair value of the acquired net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the license held by Decahedron for the wholesale of pharmaceuticals in the United Kingdome and Europe, the remainder has been allocated to goodwill, none of which is tax deductible. During the nine months ended September 30, 2017, we recorded an adjustment of $28,002 primarily related to other assets and an adjustment of the accounts payable associated with the Decahedron acquisition. We finalized our allocation of the purchase price during the nine months ended September 30, 2017. The final unaudited allocation of purchase price as of September 30, 2017, is as follows: Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884 The components of the acquired intangible assets were as follows (in thousands): Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 - _____________ (a) U.K Pharmaceutical Wholesale Distribution License Unaudited Supplemental Pro Forma Data The pro forma statements of operations data for the nine months ended September 30, 2017, below, give effect to the Decahedron Acquisition, described above, as if it had occurred at January 1, 2017. These amounts have been calculated after applying our accounting policies and adjusting the results of Decahedron intangible amortization that would have been charged assuming the fair value adjustments had been applied and incurred since January 1, 2017. This pro forma data is presented for informational purposes only and does not purport to be indicative of our future results of operations. Revenue of $2,622,547 and net loss of $255,672 since the acquisition date are included in the consolidated statement of operations and comprehensive income (loss) for nine months ended September 30, 2017. Unaudited proforma results of operations for the nine months ended September 30, 2017 and 2016 as though the Company acquired Decahedron on the first of each fiscal year are set forth below. Nine Months Ended September 30, 2017 2016 Revenues $ 19,968,845 $ 5,007,806 Cost of revenues 18,356,228 4,672,794 Gross profit 1,612,617 335,012 Operating expenses 4,411,620 614,515 Operating loss (2,799,003 ) (279,503 ) Other income (expense) (524,952 ) (238,528 ) Net Loss $ (3,323,955 ) $ (518,031 ) The purchase price exceeded the estimated fair value of the net assets acquired by $1,949,884 which was recorded as Goodwill. Goodwill represents the difference between the total purchase price for the net assets purchased from Decahedron and the aggregate fair values of tangible and intangible assets acquired, less liabilities assumed. At the conclusion of the acquisition, goodwill was reviewed for impairment and it was determined that indicators of impairment existed. As of September 30, 2017, after our assessment of the totality of the events that could impair goodwill, it was the Company’s conclusion “it is not more likely than not” that the Goodwill was impaired. Therefore, the Company was not required to conduct a two-step quantitative goodwill impairment test. No events have occurred after September 30, 2017 that would affect the Company’s conclusion as of the September 30, 2017 assessment date. As a result of the Company’s assessment, 100% of the goodwill of $1,949,884 was recorded as an impairment of goodwill.

PREPAID DEFERRED FINANCING COST

PREPAID DEFERRED FINANCING COSTS	9 Months Ended
	Sep. 30, 2017
Notes to Financial Statements
NOTE 4 - PREPAID DEFERRED FINANCING COSTS	On February 28, 2016, the Company entered into an agreement with Synthesis Management Limited (“Synthesis Management”) for the purpose of securing additional financing for the Company. On September 28, 2016, the Company advanced €125,000 ($133,725) to Synthesis Management. These advances are refundable if funding is not secured and if funding is secured, the amount will be applied to the note on day one as debt discount. As of September 30, 2017, the outstanding balance on the advance is €125,000 ($147,662). In August, 2017 the Company entered into an agreement with Synthesis Multi Asset Architecture (“Synthesis Architecture”) for the purpose of securing additional financing for the Company. On August 14, 2017, the Company advanced Synthesis Architecture €180,840 ($213,627). These advances are refundable if funding is not secured and if funding is secured, the amount will be applied to the note on day one as debt discount. As of September 30, 2017, the outstanding balance on the advance is €180,840 ($213,627).

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 5 - INCOME TAXES	At September 30, 2017, the Company’s effective tax rate differs from the US federal statutory tax rate primarily due to a valuation allowance recorded against net deferred tax assets in all jurisdictions in which the Company operates. At December 31, 2016, the Company’s effective tax rate differed from the US federal statutory tax rate primarily due to earnings taxed at the lower income tax rate in Cyprus. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At September 30, 2017, the Company has a maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. As of September 30, 2017 the Company has no uncertain tax positions recorded in any jurisdiction where it is subject to income tax. The Company has recorded $63,724 of interest and penalties as interest expense for the nine months ended September 30, 2017 in accordance with this policy.	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2016 and 2015 is as follows: 12/31/2016 12/31/2015 US Income before income taxes $ (592,288 ) $ (6,687,709 ) Taxes under statutory US tax rates $ (201,378 ) $ (2,273,821 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 193,451 $ 159,457 Foreign tax rate differential $ 19,122 $ 2,126,593 Permanent differences $ 360 $ 183 State taxes $ (11,594 ) $ (12,412 ) Income tax expense $ (39 ) $ - The increase in the Company's effective tax rate in the previous years was primarily attributable to an increase in revenue in Cyprus, which maintains a corporate income tax rate of 12.5%. The corporate income tax rate in Greece is 29%.The net increase in the valuation allowance was caused by the reversal of certain financial reporting accruals that were not previously deducted for tax. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities consist of the following: 12/31/2016 12/31/2015 US Net operating loss carry forward $ 329,848 $ 247,025 Greece Net operating loss carry forward 176,443 77,319 Cyprus Net operating loss carry forward 11,052 11,018 Total deferred tax asset 517,343 335,362 Valuation allowance (517,343 ) (335,362 ) Deferred tax asset, net $ -- $ - At December 31, 2016, the Company had US net operating loss carry forwards of approximately $329,848 that may be offset against future taxable income, subject to limitation under IRC Section 382, which begin to expire in 2031. At December 31, 2016, the Company had Greece net operating loss carry forwards of approximately $176,443 that may be offset against future taxable income which begin to expire in 2019. During the period ending December 31, 2016, the Company generated Cyprus net operating loss carry forwards of $11,052 which may be carryforward for five (5) years. The Company does not anticipate to generate taxable income in Cyprus in excess of its Cyprus net operating losses No tax benefit has been reported in the December 31, 2016 or 2015 consolidated financial statements due to the uncertainty surrounding the realizability of the benefit, based on a more likely than not criteria and in consideration of available positive and negative evidence. The Company asserts that it will indefinitely reinvest the unremitted earnings and profits generated by Amplerissimo, their Cyprus subsidiary, in 2015. Accordingly, no US deferred tax liability has been established for the unremitted earnings and profits generated in Cyprus. The Company applied the "more-likely-than-not" recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2016 and December 31, 2015, respectively. The Company has elected to classify interest and penalties that would accrue according to the provisions of relevant tax law as interest and other expense, respectively. As of December 31, 2016 the Company has accrued approximately $86,409 in other expense. The Company's tax years since inception through 2016 remain open to examination by most taxing authorities. Taxes payable are $1,080,590 and $1,032,128 as of December 31, 2016 and December 31, 2015, respectively.

CAPITAL STRUCTURE

CAPITAL STRUCTURE	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 6 - CAPITAL STRUCTURE	Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, which have liquidation preference over the common stock and are non-voting. As of September 30, 2017 and December 31, 2016, no preferred shares have been issued. Common Stock The Company is authorized to issue 300 million shares of common stock and had issued 10,000,000 in connection with the merger with Amplerissimo and had 2,558,553 shares issued prior to the merger. Under the Exchange Agreement, the Registrant completed the acquisition of all of the issued and outstanding shares of Amplerissimo through the issuance of 10,000,000 restricted shares of Common Stock to Dimitrios Goulielmos, the sole shareholder of Amplerissimo. Immediately prior to the Exchange Agreement transaction, the Registrant had 2,558,553 shares of Common Stock issued and outstanding. Immediately after the issuance of the shares the Registrant had 12,558,553 shares of Common Stock issued and outstanding. The consideration provided pursuant to the Exchange Agreement was the issuance of 10,000,000 shares of our common stock. On February 10, 2017 the Company and Decahedron consummated the acquisition of Decahedron SPA. Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company, which were delivered at closing in exchange for all of the Ordinary Shares of Decahedron for the Stock Consideration. Shares Issued for Services On March 1, 2017, the Company entered into a four-month consulting agreement with a third party investment advisory firm for consideration of 500 restricted shares of common stock to be issued during the period of the agreement for any introductions and related contributions the Company receives as a result of those introductions. As of September 30, 2017, no consideration has been earned and no shares have been issued related to this agreement. On May 1, 2017, the Company entered into an 8-month consulting agreement with a third party for web design services commencing on May 1, 2017 and terminating on January 1, 2018. As compensation for creating, delivering and maintaining a website, the Company issued 2,000 shares of common stock on May 24, 2017. The shares were valued at $14,400, which was fully recognized in the nine months ended September 30, 2017. On May 1, 2017, the Company entered into a five-month consulting agreement with a third party advisory firm for consideration of 2,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.20 per share or $14,400, which was fully recognized in the nine months ended September 30, 2017. On May 8, 2017, the Company entered into a one-year consulting agreement for advisory services with a third party investment relations firm. On May 18, 2017, the Company issued to the consultant 30,000 shares of the Company’s common stock valued at $219,000. The shares are considered to be a fully earned, nonrefundable, non-apportionable and non-ratable retainer as consideration for undertaking the agreement. In addition, the Company will pay the consultant $5,000 per month in cash for the term of the agreement. On May 25, 2017, the Company entered into a 20-month consulting agreement with a third party advisory firm for consideration of 20,000 shares of the Company’s common stock. The stock was issued on May 25, 2017 and fair valued at $7.70 per share or $154,000, which will be amortized over the length of the agreement. For the nine months ending September 30, 2017, the Company has recorded $32,874 in consulting expense related to this agreement. As of September 30, 2017 and December 31, 2016, the Company had 12,825,393 and 12,587,053 shares of Common Stock issued and outstanding, respectively. Potentially Dilutive Securities On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of September 30, 2017. (See Note 10) On January 1, 2017 the Company granted 25,000 options to an employee of the Company as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 18,750 options fully vested as of September 30, 2017. (See Note 10) On January 3, 2017 the Company granted 12,000 options to an employee of the Company as compensation for being appointed as a consultant of the Company. The options have an exercise period of five years with an exercise price of $2.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 9,000 options fully vested as of September 30, 2017. (See Note 10) Sales Pursuant to Regulation S On April 7, 2017, the Company issued shares of common stock and warrants pursuant to a private placement conducted under the exemptions from registration under Regulation S. Each unit sold to investors consists of $35,000 face value purchase price of 5,000 shares plus warrants to purchase the number of equivalent shares. The Company retains the right to accept less than the $35,000 face value from any investor at its discretion. The Company has entered into the following subscription agreements: On April 10, 2017, the Company sold 4,580 shares at $7.00 per share for a total purchase price of $32,060 to a private investor. The investor also received 4,580 warrants that were valued using the Black Scholes valuation model to have a fair value of $2,375 (See Note 10). On April 26, 2017, the Company sold 4,670 shares at $7.00 per share for a total purchase price of $32,690 to a private investor. The investor also received 4,670 warrants that were valued using the Black Scholes valuation model to have a fair value of $1,521 (See Note 10). On May 16, 2017, the Company sold 790 shares at $7.00 per share for a total purchase price of $5,530 to a private investor. The investor also received 790 warrants that were valued using the Black Scholes valuation model to have a fair value of $130 (See Note 10). On July 21, 2017, the Company sold 4,300 shares at $5.00 per share for a total purchase price of $21,500 to a private investor. The Company did not grant any warrants to the investor under this agreement. No options, warrants or other potentially dilutive securities other than those disclosed above have been issued as of September 30, 2017 and December 31, 2016.	Common Stock The Company is authorized to issue 300 million shares of common stock and had issued 100,000,000 in connection with the merger and had 2,558,553 shares issued prior to the merger. Under the Exchange Agreement, the Registrant completed the acquisition of all of the issued and outstanding shares of Amplerissimo through the issuance of 10,000,000 restricted shares of Common Stock to Dimitrios Goulielmos, the sole shareholder of Amplerissimo. Immediately prior to the Exchange Agreement transaction, the Registrant had 2,558,553 shares of Common Stock issued and outstanding. Immediately after the issuance of the shares the Registrant had 12,558,553 shares of Common Stock issued and outstanding. The consideration provided pursuant to the Exchange Agreement was the issuance of 10,000,000 shares of our common stock. On April 28, 2015, the Company issued 4,500 shares of common stock to Hellenic American Securities for consulting services and has recorded consulting expense of $28,352 for the year ended December 31, 2015 based on the share price on the date of issuance. The terms of the consulting agreement call for payments of $1,000 per month plus 18,000 shares on an annual basis which will be issued quarterly. As of November 19, 2015, this agreement has been terminated due to lack of service. No additional shares will be issued under this agreement. On November 4, 2016, the Board of Directors authorized the exercise of stock options held by a former director to purchase 24,000 shares of common stock and the Company recorded $24,000 in proceeds. (See Note 10.) As of December 31, 2016 and 2015, the Company had 12,587,053 and 12,563,053 shares of Common Stock issued and outstanding, respectively. Preferred Stock The Company is authorized to issue 100 million shares of preferred stock, which have liquidation preference over the common stock and are non-voting. As of December 31, 2016 and 2015, no preferred shares have been issued. Potentially Dilutive Securities On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 3,000 options fully vested as of December 31, 2016. (See Note 10.) No options, warrants or other potentially dilutive securities other than those disclosed above have been issued as of December 31, 2016 and 2015.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 7 - RELATED PARTY TRANSACTIONS	On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in Common Stock and Additional Paid in Capital). DOC Pharma S.A. As of September 30, 2017, the Company has a prepaid balance of €347,914 ($410,991) to DOC Pharma S.A., this comprises over 10.3% of the Company’s total prepaid balance. As of December 31, 2016, the Company owed €65 ($69) to DOC Pharma S.A. On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with DOC Pharma S.A, pursuant to which DOC Pharma S.A., paid existing bills of the Company in the amount of €12,000, excluding the Vendor Bills. The loan bears an interest rate of 2% per annum and was due and payable in full on October 31, 2016. As of September 30, 2017, the Company has an outstanding principal balance under this note of €12,000 ($14,176) and accrued interest expense of $612. Grigorios Siokas On October 1, 2016, the Company borrowed €5,000 ($5,276) from Mr. Siokas related to its subsidiary’s purchase of additional capital of SkyPharm. The loan is non-interest bearing and has a maturity date of October 1, 2017. During the nine months ending September 30, 2017, the Company borrowed an additional €1,000 ($1,181). The outstanding balance as of September 30, 2017 was €6,000 ($7,088). During the year ended December 31, 2016, the Company borrowed €90,500 ($95,496) as additional loans payable from Mr. Siokas. During the nine months ended September 30, 2017, the Company borrowed an additional €473,621 ($559,488) and paid back €123,000 ($145,300) of these loans. These loans have no formal agreements and bear no interest. As 1of September 30, 2017, the Company has an outstanding principal balance under these loans of €441,121 ($521,096). As of September 30, 2017, the Company has recorded €59,646 ($70,459) in prepayments to Mr. Siokas for board of directors fees. Ourania Matsouki During the year ended December 31, 2016, the Company borrowed €44,995 ($47,479) from Mrs. Matsouki. During the nine months ended September 30, 2017, the Company borrowed an additional €55,000 ($64,982) and paid back €73,437 ($86,751). These loans have no formal agreement and bear no interest. As of September 30, 2017, the Company has an outstanding principal balance under these loans of €26,558 ($31,373). Konstantinos Vassilopoulos During the year ended December 31, 2016, Konstantinos Vassilopoulos, US Finance Manager, paid $10,179 of existing bills of the Company. During the nine months ended September 30, 2017, the Company paid back $9,810. There is no formal agreement related to these transactions. As of September 30, 2017 the outstanding balance under this loan is $369. Dimitrios Goulielmos On November 21, 2014, SkyPharm entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company, pursuant to which the Borrower borrowed €330,000 ($401,115) from Mr. Goulielmos. The Loan bears an interest rate of 2% per annum and was due and payable in full on May 11, 2015. On November 4, 2015, €130,000 ($142,860) in principal and the related accrued interest of €733 ($806) was forgiven and the remaining balance of €200,000 will no longer accrue interest as part of the stock purchase agreement with Grigorios Siokas on November 4, 2015 referenced above. As of December 31, 2016, €60,000 ($63,312) of the loan was paid back. During the nine months ended September 30, 2017 an additional €53,500 ($63,200) was paid back and a principal balance of €86,500 ($102,182) and €0.00 of accrued interest remains. In connection with the Decahedron SPA, on February 9, 2017, Decahedron, Medihelm S.A. and Nikolaos Lazarou entered into a liability transfer agreement whereby the loan previously provided Decahedron to the Mr. Lazarou prior to the acquisition would be cancelled in exchange for Mr. Lazarou’s personal assumption of approximately £172,310 ($220,988) owed to MediHelm S.A., a creditor of Decahedron. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.	On the date of our inception, we issued 2 million shares of our common stock to our three officers and directors which were recorded at no value (offsetting increases and decreases in Common Stock and Additional Paid in Capital). DOC Pharma S.A. As of December 31, 2016, the Company has a prepaid balance of €65 ($69) to DOC Pharma S.A., this comprises over 13% of the Company's total prepaid balance. As of December 31, 2015, the Company owed €111,000 ($121,063) to DOC Pharma S.A. On November 1, 2015, the Company entered into a €12,000 ($12,662) Loan Agreement with DOC Pharma S.A, pursuant to which DOC Pharma S.A., paid existing bills of the Company in the amount of €12,000, excluding the Vendor Bills. The loan will bear an interest rate of 2% per annum and will be due and payable in full on October 31, 2016. As of December 31, 2016, the Company has an outstanding principal balance under this note of €12,000 ($12,662) and accrued interest expense of $308. Grigorios Siokas As of December 31, 2016 the Company has prepaid expenses of €14,646 ($15,454) related to board of directors' fees and related taxes for Grigorios Siokas, Chief Executive Officer. During the year ended December 31, 2015, the Company borrowed €10,000 ($10,906) as loan payable from Mr. Grigorios Siokas. The loan has no formal agreement and bears no interest. During the year ended December 31, 2016, this loan has been paid back in full. On October 1, 2016, the Company borrowed €5,000 ($5,276) from Mr. Siokas related to its subsidiary’s purchase of additional capital of SkyPharm. The loan is non-interest bearing and has a maturity date of October 1, 2017. The outstanding balance as of December 31, 2016 was €5,000 ($5,276). During the year ended December 31, 2016, the Company borrowed €90,500 ($95,496) as an additional loan payable from Mr. Siokas. This loan has no formal agreement and bears no interest. As of December 31, 2016, the Company has an outstanding principal balance under this loan of €90,500 ($95,496). Ourania Matsouki During the year ended December 31, 2015, the Company borrowed €4,500 ($4,908) from Mrs. Ourania Matsouki, wife of Mr. Grigorios Siokas, Chief Executive Officer. This loan has no formal agreement and bears no interest. This loan was paid back in full during the year ended December 31, 2016. During the year ended December 31, 2016, the Company borrowed an additional €44,995 ($47,479) from Mrs. Matsouki. This loan has no formal agreement and bears no interest. As of December 31, 2016, the Company has an outstanding principal balance under this loan of €44,995 ($47,479). Konstantinos Vassilopoulos During the year ended December 31, 2016, Konstantinos Vassilopoulos, US Finance Manager, paid $10,179 of existing bills of the Company. There is no formal agreement related to these transactions. Dimitrios Goulielmos On August 17, 2015, the Company entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current Director of the Company, pursuant to which the Company borrowed $50,000 from Mr. Goulielmos. The loan will bear an interest rate of 2% per annum and is due and payable in full on December 15, 2016. As documented in Form 8-K that was filed on November 09, 2015, the loan amount has been fully forgiven by Mr. Goulielmos and was written off as of December 31, 2015. On March 27, 2015, the Company entered into a Loan Agreement with Dimtrios Goulielmos, former Chief Executive Officer and a current Director of the Company, pursuant to which the Company borrowed $70,000 from Mr. Goulielmos. The loan will bear an interest rate of 2% per annum and is due and payable in full on December 15, 2015. As documented in Form 8-K that was filed on November 09, 2015, the loan amount has been fully forgiven by Mr. Goulielmos and was written off as of December 31, 2015. On December 29, 2014, the Company entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company, pursuant to which the Company borrowed $100,000 from Mr. Goulielmos. The Loan will bear an interest rate of 2% per annum and will be due and payable in full on June 30, 2015. As documented in Form 8-K that was filed on November 09, 2015, the loan amount has been fully forgiven by Mr. Goulielmos and was written off as of December 31, 2015. On November 21, 2014, SkyPharm entered into a Loan Agreement with Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company, pursuant to which the Borrower borrowed €330,000 ($401,115) from Mr. Goulielmos. The Loan will bear an interest rate of 2% per annum and will be due and payable in full on May 11, 2015. On November 4, 2015, €130,000 ($142,860) in principal and the related accrued interest of €733 ($806) was forgiven and the remaining balance of €200,000 will no longer accrue interest as part of the stock purchase agreement with Grigorios Siokas on November 4, 2015 referenced above. As of December 31, 2016, €60,000 ($63,312) of the loan was paid back, and a principal balance of €140,000 ($147,728) and €0.00 of accrued interest remains. During 2015, the aggregate forgiveness of related party notes of $362,859 was accounted for as a capital transaction. In 2014, the aggregate forgiveness of accrued salaries resulted in a gain of $173,092. On December 29, 2014, the Company borrowed $3,000 from Dimitrios Goulielmos, former Chief Executive Officer and a current director of the Company. The loan was non-interest bearing and was repaid in full in January 2015. November 2015 Stock Purchase Agreement On November 4, 2015, Mr. Dimitrios Goulielmos (the "Seller") and Mr. Grigorios Siokas (the "Buyer") entered into a stock purchase agreement, whereby Mr. Goulielmos sold 9,500,000 shares of common stock to Mr. Siokas for $1.00. As part of the agreement, the Seller forgave and released the Company and the Company's subsidiary from all claims except for the repayment of €200,000 that was loaned by the Seller to SkyPharm. In exchange, the Buyer pledged to pay various obligations of the Company as listed in the Annex of the agreement as follows: $16,357 to Malone Bailey, $3,000 in accounting fees, $2,400 to Terzis, the Amplerissimo tax liability of €817,811 and various other obligations estimated between $5,000 and $10,000 (collectively the "Vendor Bills"). The Company subsequently paid the Vendor Bills. Notwithstanding the non-payment of the Vendor Bills by the buyer at that time, in connection with the sale of common stock to Mr. Siokas, on February 26, 2016, Dimitrios Goulielmos resigned from his positions as Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO") of Cosmos Holdings, Inc. (the "Company") but retained his position as a director on the Board of Directors. The Board of Directors appointed Grigorios Siokas to the offices of CEO and CFO and elected him to fill a vacancy and serve on the Board of Directors and as the Chairman of the Board. We believe that all related party transactions were on terms at least as favorable as we would have secured in arm's-length transactions with third parties. Except as set forth above, we have not entered into any material transactions with any director, executive officer, and promoter, beneficial owner of five percent or more of our common stock, or family members of such persons.

DEBT

DEBT	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 8 - DEBT	On March 4, 2015, the Company entered into a $9,000 Loan Agreement with Mr. Angelo Drakopoulos, pursuant to which Mr. Drakopoulos paid a $9,000 outstanding bill on behalf of the Company. The loan bears an interest rate of 8% per annum and was due and payable in full on May 5, 2016. As of September 30, 2017, the Company has an outstanding principal balance under this note of $9,000 and accrued interest expense of $1,345. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,812), of which proceeds of €10,000 ($10,906) have been received as of December 31 2016. The loan bears an interest rate of 1% per annum and was due and payable in full on November 5, 2016. The Company repaid €2,000 ($2,110) as of December 31, 2016. The Company has repaid an additional €8,000 ($9,450) as of September 30, 2017. The Company has accrued interest expense of €435 ($514) and an outstanding balance under this note of €10,000 ($11,813) as of September 30, 2017. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €80,000 ($87,248) of which proceeds of €70,000 ($76,342) have been received as of December 31, 2016. The loan bears an interest rate of 5% per annum and was due and payable in full on November 5, 2016. As of December 31, 2016, the outstanding balance was €65,000 ($68,588). During the nine months ended September 30, 2017, the Company repaid €55,000 ($64,972) and reversed the €10,000 ($11,813) receivable that was never received. On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($43,624) as a note payable from Mr. Drakopoulos. The note bears an interest rate of 6% per annum and was due and payable in full on November 15, 2016. The Company repaid €10,000 ($11,813) during the nine months ended September 30, 2017. As of September 30, 2017, the Company has an outstanding principal balance under this note of €30,000 ($35,439) and accrued interest expense of €4,064 ($4,801). During the year ended December 31, 2015, the Company borrowed €30,000 ($32,718) as a loan payable from Mr. Panagiotis Drakopoulos, former Director and former Chief Executive Officer. The loan had no formal agreement and bore no interest. During the year ended December 31, 2016, the Company repaid €13,000 ($13,718) of the loan. During the nine months ended September 30, 2016 the Company repaid the remaining €17,000 ($20,082). As of September 30, 2017, the loan has no outstanding balance. On February 5, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,104). The loan bore an interest rate of 6% and had no maturity date. During the nine months ended September 30, 2017, the Company repaid the loan and accrued interest of €1,020 ($1,204) in full. On March 4, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760) from a third party. On May 04, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed an additional €50,000 ($52,760). The loans bore an interest rate of 6% and a maturity date of March 4, 2017 and May 4, 2017, respectively. During the nine months ended September 30, 2017, the Company repaid both loans and accrued interest of €750 ($886) in full. On April 19, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €100,000 ($105,520). The loan bore an interest rate of 6% and matured on April 19, 2017. During the nine months ended September 30, 2017, the Company repaid the loan and accrued interest of €3,100 ($3,662) in full. On April 22, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €38,000 ($40,098). The loan bore an interest rate of 6% and matured on April 22, 2017. During the nine months ended September 30, 2017, the Company repaid the loan and accrued interest of €1,777 ($2,099) in full. On May 24, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760). The loan bears an interest rate of 6% and matured on May 24, 2017. During the nine months ended September 30, 2017, the Company repaid the principal balance of €50,000 ($59,065) in full. The Company has accrued interest expense of €2,798 ($3,305) as of September 30, 2017. On October 18, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €10,000 ($10,552). The loan bears an interest rate of 10% and will mature on October 18, 2017. During the nine months ended September 30, 2017, the Company repaid the principal balance of €10,000 ($11,813) in full. The Company has accrued interest expense of €239 ($283) as of September 30, 2017. Loan Facility Agreement On August 4, 2016, the Company’s wholly owned subsidiary SkyPharm entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the “Loan Facility” the “Lender”). The Loan Facility initially provided SkyPharm with a credit facility of up to $1,292,769 (€1,225,141). Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the Lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement as amended is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. On September 13, 2016, Sky Pharm entered into a First Deed of Amendment with the Loan Facility increasing the maximum loan amount to $1,533,020 as a result of the Lender having advanced $240,251 (€227,629) to SkyPharm. On March 23, 2017, SkyPharm entered into an Amended and Restated Loan Facility Agreement (the “A&R Loan Facility”), with the Loan Facility which increased the loan amount to an aggregate total of $2,664,960 (€2,491,083) as a result of the lender having advanced $174,000 (€164,898) in September 2016, $100,000 (€94,769) in October 2016, $250,000 (€236,922) in November 2016, $452,471 (€428,800) in December 2016, $155,516 (€131,648) in January 2017 and $342,327 (€289,788) in July 2017. The A&R Loan Facility amends and restates certain provisions of the Loan Facility Agreement, dated as of August 4, 2016, by and among the same parties. Advances under the A&R Loan Facility continue to accrue interest at a rate of 10% per annum from the applicable date of each drawdown and require quarterly interest payments. The A&R Facility now permits prepayments at any time. The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018. The A&R Loan Facility is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas (the “Pledged Shares”). The A&R Loan Facility was also amended to provide additional affirmative and negative covenants of Sky Pharm and the Guarantor during the term of loans remain outstanding, including, but not limited to, the consent of the Lender in connection with (i) the Company or any of its subsidiaries incurring any additional indebtedness; or (ii) in the event of any increase in the Company’s issued and outstanding shares of Common Stock, the Pledged Shares shall be increased to an amount equal to a minimum of ten percent (10%) of the issued and outstanding shares of the Company. As of September 30, 2017, the outstanding balance under this note was $3,007,287 (€2,545,744) and accrued interest expense of $143,761 (€121,697) has been recorded. The Company recorded €120,000 ($141,756) in debt discounts related to this note. The debt discounts are being amortized over the term of the debt. During the year ended December 31, 2016 the Company amortized a total of $14,507 (€13,748). Amortization of the debt discounts for the nine months ended September 30, 2017 was $52,796 (€47,368). Bridge Loans On March 16, 2017 and March 20, 2017, SkyPharm entered into loan agreements with the Synthesis Peer-To Peer-Income Fund (the “Bridge Loans”). The Bridge Loans provided to SkyPharm loans of €42,326 ($50,000) and €100,000 ($118,130), respectively. The Bridge Loans accrue interest at a rate of 10% per annum and were repayable on April 16, 2017 and April 20, 2017, respectively together with all other amounts then accrued and unpaid. On April 16, 2017, the maturity dates were amended for no additional consideration of change in terms and conditions. The maturity dates of both loans were amended and they matured on May 16, 2017 and May 20, 2017, respectively. The Company has accrued interest expense of an aggregate total of €7,335 ($8,665) for both loans and the outstanding balances of these loans was €42,326 ($50,000) and €100,000 ($118,130), respectively, as of September 30, 2017. On May 5, 2017, SkyPharm entered into a loan agreement with Synthesis Peer-To-Peer Income Fund for €30,449 ($34,745). The loan accrues interest at a rate of 10% per annum and matures on September 30, 2017. The Company as accrued interest expense of €1,201 ($1,418) and the outstanding balance on this loan was €29,413 ($34,745) as of September 30, 2017. Trade Facility Agreements On April 10, 2017, Decahedron entered into a Trade Finance Facility Agreement (the “Decahedron Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The Decahedron Facility provides the following material terms: · The Lender will provide Decahedron a facility of up to €2,750,000 ($2,941,950) secured against Decahedron’s receivables from the sale of branded and generic pharmaceutical sales. · The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. · The term of the Decahedron Facility will be for 12 months. · The obligations of Decahedron are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. · The Lender has the right to make payments directly to Decahedron’s suppliers. · The following fees should be paid in connection with the Decahedron Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The current draw on the Decahedron Facility is $0. On May 12, 2017, SkyPharm entered into a Trade Finance Facility Agreement (the “SkyPharm Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The SkyPharm Facility provides the following material terms: · The Lender will provide SkyPharm a facility of up to €2,000,000 ($2,282,200) secured against SkyPharm’s receivables from the sale of branded and generic pharmaceutical sales. In the event that accounts receivable becomes uncollectible, the Company will be obligated to pay back the notes in full. · The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. · The term of the SkyPharm Facility will be for 12 months. · The obligations of SkyPharm are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. · The Lender has the right to make payments directly to SkyPharm’s suppliers. · The following fees should be paid in connection with the SkyPharm Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The current draw on the SkyPharm Facility is €5,216,910 ($6,162,736) and the Company has accrued €170,711 ($201,661) in monthly fees related to this agreement. The Company obtained consents from Synthesis Peer-to-Peer Income Fund in connection with obtaining the Lender. On November 16, 2017, the Company signed an amendment to the agreement for the additional proceeds borrowed. The Company has recorded a total debt discount of €104,338 in origination fees associated with these loans, which will be amortized over the term of the agreements. Amortization of debt discount for the nine months ended September 30, 2017 was €31,295 ($34,881). None of the above loans were made by any related parties.	On March 4, 2015, the Company entered into a $9,000 Loan Agreement with Mr. Angelo Drakopoulos, pursuant to which Mr. Drakopoulos paid a $9,000 outstanding bill on behalf of the Company. The loan will bear an interest rate of 8% per annum and will be due and payable in full on May 5, 2016. As of December 31, 2016, the Company has an outstanding principal balance under this note of $9,000 and accrued interest expense of $814. On November 5, 2015, the Company entered into a Loan Agreement pursuant to which the Company borrowed €80,000 ($87,248) of which proceeds of €70,000 ($76,342) have been received as of December 31, 2016. The loan will bear an interest rate of 5% per annum and is due and payable in full on November 5, 2016. The Company has accrued interest expense of €8,315 ($8,774) as of December 31, 2016. The outstanding balance under this note was €65,000 ($68,588) as of December 31, 2016. On November 16, 2015, the Company entered into a Loan Agreement with Panagiotis Drakopoulos, former Director and former Chief Executive Officer, pursuant to which the Company borrowed €40,000 ($43,624) as a note payable from Mr. Drakopoulos. The note will bear an interest rate of 6% per annum and is due and payable in full on November 15, 2016. As of December 31, 2016, the Company has an outstanding principal balance under this note of €40,000 ($42,208) and accrued interest expense of €2,710 ($2,860). During the year ended December 31, 2015, the Company borrowed €30,000 ($32,718) as a loan payable from Mr. Panagiotis Drakopoulos, former Director and former Chief Executive Officer. The loan has no formal agreement and bear no interest. During the year ended December 31, 2016, the Company repaid €13,000 ($13,718) of the loan. As of December 31, 2016, the Company has an outstanding principal balance under this note of €17,000 ($17,938). During the year ended December 31, 2015, the Company borrowed €30,000 ($32,718) from a third party. There was no formal agreement and the loan bears no interest. During the year ended December 31, 2016 this loan was paid back in full. On January 6, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €150,000 ($158,280). The loan will bear an interest rate of 1% per annum and is due and payable in full on February 6, 2016. As of December 31, 2016, the loan and accrued interest of €458 ($483) was paid back by in full by the Company. On February 5, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €20,000 ($21,104). The loan will bear an interest rate of 6% and has no maturity date. The Company has accrued interest expense of €1,090 ($1,150) as of December 31, 2016. The outstanding balance under this note was €20,000 ($21,104) as of December 31, 2016. On March 4, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760). The loan will bear an interest rate of 6% and a maturity date of March 4, 2017. The Company has accrued interest expense of €0.00 as of December 31, 2016. The outstanding balance under this note was €50,000 ($52,760) as of December 31, 2016. On April 19, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €100,000 ($105,520). The loan will bear an interest rate of 6% and will mature on April 19, 2017. The Company has accrued interest expense of €2,226 ($2,349) as of December 31, 2016. The outstanding balance under this note was €100,000 ($105,520) as of December 31, 2016. On April 22, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €38,000 ($40,098). The loan will bear an interest rate of 6% and will mature on April 22, 2017. The Company has accrued interest expense of €1,587 ($1,675) as of December 31, 2016. The outstanding balance under this note was €38,000 ($40,098) as of December 31, 2016. On May 04, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760). The loan will bear an interest rate of 6% and will mature on May 4, 2017. The Company has accrued interest expense of €560 ($590) as of December 31, 2016. The outstanding balance under this note was €50,000 ($52,760) as of December 31, 2016. On May 24, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €50,000 ($52,760). The loan will bear an interest rate of 6% and will mature on May 24, 2017. The Company has accrued interest expense of €1,827 ($1,928) as of December 31, 2016. The outstanding balance under this note was €50,000 ($52,760) as of December 31, 2016. On October 18, 2016, the Company entered into a Loan Agreement pursuant to which the Company borrowed €10,000 ($10,552). The loan will bear an interest rate of 10% and will mature on October 18, 2017. The Company has accrued interest expense of €203 ($214) as of December 31, 2016. The outstanding balance under this note was €10,000 ($10,552) as of December 31, 2016. Loan Facility Agreement On August 4, 2016, the Company's wholly owned subsidiary SkyPharm entered into a Loan Facility Agreement, guaranteed by Grigorios Siokas, with Synthesis Peer-To Peer-Income Fund (the "Loan Facility" the “Lender”). The Loan Facility initially provided SkyPharm with a credit facility of up to $1,292,769 (€1,225,141). Any advance under the Loan Facility accrues interest at a rate of 10% per annum and requires quarterly interest payments commencing on September 30, 2016. The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility. The Synthesis Facility Agreement is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas. On September 13, 2016, Sky Pharm entered into a First Deed of Amendment with the Loan Facility increasing the maximum loan amount to $1,533,020 as a result of the lender having advanced $240,251 (€227,629) to SkyPharm. On March 23, 2017, SkyPharm entered into a Second Deed of Amendment with the Loan facility which increased the loan amount to an aggregate total of $2,664,960 (€2,525,550) as a result of the lender having advanced $174,000 (€164,898) in September, $100,000 (€94,769) in October 2016, $250,000 (€236,922) in November 2016, $452,471 (€428,800) in December 2016 and $155,516 (€147,381) in January 2017. As of December 31, 2016, the outstanding balance under this note was $2,509,444 (€2,378,169) and accrued interest expense of €49,928 ($47,316) has been recorded. The Company recorded €120,000 ($126,624) in debt discounts related to this note. The debt discounts are being amortized over the term of the debt. Amortization of the debt discounts for the year ended December 31, 2016 was €14,507 ($16,063). None of the above loans were made by any related parties.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 9 - COMMITMENTS AND CONTINGENCIES	Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of September 30, 2017, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations. Operating Leases The Company conducts its operations from an office located in Chicago, Illinois for which beginning in January 2015, the monthly rent expense is $730, which has been paid through December 31, 2015. The lease expired as of November 30, 2015, however, the Company has negotiated and entered into a new lease that commenced as of September 1, 2016 at a rate of $709 per month. Rent expense for the three and nine months ended September 30, 2017 was $2,126 and $6,377, respectively. Rent expense for the three and nine months ended September 30, 2016, was $2,126 and $2,834, respectively. The offices of Amplerissimo are located in Cyprus for which we paid approximately €110 ($122) per month on a month to month basis. Rent expense for the three and nine months ended September 30, 2017 was €330 ($368) and €990 ($1,103), respectively. Rent expense for the three and nine months ended September 30, 2016 was €330 ($368) and €990 ($1,105), respectively. The offices of SkyPharm are located in Greece, Thessaloniki, for which we paid approximately €4,325 ($4,802) per month under a six year lease that commenced September 2014. In December 2015, the lease was revised to include an additional rental of the first floor at a rate of €800 ($886) per month. The lease was further revised in March 2016 to include another additional rental of the first floor at a rate of €800 ($886) per month beginning in May 2016. On May 30, 2016, the lease was revised again to include an additional rental of space at a rate of €1,825 ($2,021) per month beginning in June 2016. On March 23, 2017, SkyPharm entered into an additional three year lease at a rate of €1,250 per month that commenced May 2017. Rent expense for the three and nine months ended September 30, 2017 was €27,000 ($30,094) and €76,000 ($84,710), respectively. Rent expense for the three and nine months ended September 30, 2016 was €23,250 ($25,961) and €57,425 ($64,127), respectively. The offices of Decahedron are located in Flex Meadow, Harlow, for which we pay approximately ₤1,908 ($2,415) per month, under a one year amendment to a lease dated October 25, 2011, which commenced on October 25, 2016. Rent expense from the date of acquisition through September 30, 2017 was ₤15,267 ($19,580). Intellectual Property Sale Agreement On October 1, 2016, the Company entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou (the “IPSA”) for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related thereto (the “Intellectual Property”). The IPSA provides that the sellers shall be entitled to an aggregate of 200,000 shares of common stock of the Company, none of which have been issued to date, and issuable as follows in equal parts to each seller: · 50,000 shares upon the successful conclusion of Preclinical Trials. · 50,000 shares upon the conclusion of Phase I testing. · 50,000 shares upon the conclusion of Phase II testing. · 50,000 shares upon the conclusion of Phase III testing. The Company has agreed to pay Anastasios Tsekas €1,500 per month until the first issuance of the shares referenced above. The Company has also agreed that in the event the Company disposes of the Intellectual Property prior to the periods referenced above, the sellers shall be entitled to the issuance of all the shares referenced above. The Company is in the process of locating a suitable lab to conduct the Preclincal trial phase, which has not yet begun as of the date of filing. Letter of Intent On June 21, 2017, the Company signed a new Letter of Intent (LOI) to acquire the outstanding shares of CC Pharma GmbH, a leading re-importer of EU pharmaceuticals to Germany. Under the terms of the LOI, Cosmos Holdings holds the exclusive right to complete its due diligence process and complete the transaction by October 31, 2017. In connection with the non-binding LOI, the Company is required to pay a non-refundable fee of €400,000 ($454,800) to the shareholders of CC Pharma GmbH in connection with the costs of due diligence and the exclusive right to negotiate the terms of the definitive agreements. On July 6, 2017, the Company paid the €400,000 ($454,800) to CC Pharma GmbH and the Company has recorded an expense of €400,000 ($454,800) for the nine months ended September 30, 2017. The Company did not enter into any definitive agreements by October 31, 2017 and is currently negotiating with CC Pharma for an extension. The Company makes no assurances that the parties will enter into any definitive agreements in the future. Placement Agreement On August 8, 2017, the Company entered into an agreement with a third party placement agent (the “Agent”) who will serve as the Company’s exclusive placement agent or sole book running manager with respect to any offerings of equity or equity-linked securities as well as any debt offering with the two organizations named in the agreement (the “Offering”) for a period of 120 days. In the event that an Offering is agreed upon by the Agent and the Company, the Company shall provide payment as follows: (1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering.	Legal Matters From time to time, the Company may be involved in litigation relating to claims arising out of the Company’s operations in the normal course of business. As of December 31, 2016, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations. Operating Leases The Company conducts its operations from an office located in Chicago, Illinois for which beginning in January 2015, the monthly rent expense is $730, which has been paid through December 31, 2015. The lease expired as of November 30, 2015, however, the Company has negotiated and entered into a new lease that commenced as of June 1, 2016 at a rate of $709 per month. Rent expense for the years ended December 31, 2016 and 2015, was $4,960 and $12,053, respectively. The offices of Amplerissimo are located in Cyprus for which we paid approximately €110 ($122) per month under a one year lease which expired in July 2013 and was renewed through July 2015, whereupon rent continued to be paid by the Company on a month to month basis. Rent expense for the years ended December 31, 2016 and 2015 was €1,320 ($1,462) and €1,320 ($1,462), respectively. The offices of SkyPharm are located in Greece, Thessaloniki, for which we paid approximately €4,325 ($4,802) per month under a six year lease that commenced September 2014. In December 2015, the lease was revised to include an additional rental of the first floor at a rate of €800 ($886) per month. The lease was further revised in March 2016 to include another additional rental of the first floor at a rate of €800 ($886) per month beginning in May 2016. On May 30, 2016, the lease was revised again to include an additional rental of space at a rate of €1,825 ($2,021) per month beginning in June 2016. Rent expense for the years ended December 31, 2016 was €80,675 ($89,323) and €54,597 ($60,614) respectively. Intellectual Property Sale Agreement On October 1, 2016, the Company entered into an Intellectual Property Sale Agreement with Anastasios Tsekas and Olga Parthenea Georgatsou (the “IPSA”) for the purchase of certain intellectual property rights relating to proprietary pharmaceutical formulas and any related technical information arising or related thereto (the “Intellectual Property”). The IPSA provides that the sellers shall be entitled to an aggregate of 200,000 shares of common stock of the Company, none of which have been issued to date, and issuable as follows in equal parts to each seller: · 50,000 shares upon the successful conclusion of Preclinical Trials. · 50,000 shares upon the conclusion of Phase I testing. · 50,000 shares upon the conclusion of Phase II testing. · 50,000 shares upon the conclusion of Phase III testing. The Company has agreed to pay Anastasios Tsekas €1,500 per month until the first issuance of the shares referenced above. The Company has also agreed that in the event the Company disposes of the Intellectual Property prior to the periods referenced above, the sellers shall be entitled to the issuance of all the shares referenced above.

EARNINGS PER SHARE

EARNINGS PER SHARE	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 8 - EARNINGS PER SHARE	Basic net income (loss) per share is computed by dividing net income (loss) attributable to the Company, decreased with respect to net income or increased with respect to net loss by dividends declared on preferred stock by using the weighted-average number of common shares outstanding. The dilutive effect of incremental common shares potentially issuable under outstanding options, warrants and restricted shares is included in diluted earnings per share in 2016 and 2015 utilizing the treasury stock method. The computations of basic and diluted per share data were as follows: 12/31/2016 12/31/2015 Net (loss) income $ (601,002 ) $ (6,687,912 ) Weighted average common shares outstanding – basic 12,564,824 12,561,598 Option awards 8,074 20,687 Weighted average common shares outstanding - dilutive 12,564,824 12,561,598 Basic and Diluted (0.05 ) (0.53 )

DEPOSIT ON PENDING ACQUISITION

DEPOSIT ON PENDING ACQUISITION	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
NOTE 9 - DEPOSIT ON PENDING ACQUISITION	On August 19, 2014, Amplerissimo Ltd., a company incorporated in Cyprus and a subsidiary of the Company ("Amplerissimo") entered into a Share Purchase Agreement (the "Purchase Agreement") with B2IN S.A., a corporation organized under the laws of Greece ("B2IN"), Unilog Logistics S.A., a corporation organized under the laws of Greece and a wholly owned subsidiary of B2IN ("Unilog"), and Wilot Limited, a corporation organized under the laws of Cyprus ("Seller"). The transaction contemplated that, at the closing (the "Closing"), Amplerissimo would have acquired from Seller all of the outstanding capital stock of B2IN for a purchase price of seven million euros (€7,000,000) or approximately $7,634,000. As of December 31, 2015, €5,540,000 ($6,041,924) of this purchase price was paid to the Seller by Amplerissimo. The Company did not consummate the closing of the transaction; however, the Company has determined that the Seller will not refund any of the amounts previously paid to B2IN. Accordingly, as of December 31, 2015, €5,540,000 ($6,041,924) was written off and the balance of the deposit account is €0.00.

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 10 - STOCK OPTIONS AND WARRANTS	On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00 per share. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 12,000 options fully vested as of September 30, 2017. The options were valued at $65,290 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $5.80; Exercise price: $2.00; Option term: 4 years; Computed volatility: 159%. The Company expensed $16,636 in the year ended December 31, 2016. As of September 30, 2017 the Company has expensed an additional $48,654. On January 1, 2017 the Company entered into an agreement whereby the employee was granted compensation of €1,000 per month and an annual retainer of 25,000 stock options as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 18,750 options fully vested as of September 30, 2017. The options were valued at $195,307 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $8.20; Exercise price: $1.00; Option term: 4 years; Computed volatility: 136.76%. The fair value of the options will be amortized over a year with $146,079 expensed during the nine months ended September 30, 2017. On January 3, 2017 the Company determined to create an advisory board and appointed Mr. Orestes Varvitsiotes as its first member. Mr. Varvitsiotes is a registered broker dealer who is currently engaged with Aegis Capital Corp. In connection therewith, the Company entered into an Advisory Board Member Consulting Agreement, dated as of January 3, 2017 whereby an annual retainer of 12,000 stock options was granted as compensation for services. The options have an exercise period of five years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly, with a total of 9,000 options fully vested as of September 30, 2017. The options were valued at $94,830 using the Black Scholes Option Pricing Model, with the following inputs: stock price on measurement date: $8.20; Exercise price: $2.00; Option term: 5 years; Computed volatility: 155.37%. The fair value of the options will be amortized over the year with $70,796 expensed during the nine months ended September 30, 2017. A summary of the Company’s option activity during the nine months ended September 30, 2017 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ 74,400 Granted 37,000 1.32 3.58 150,800 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2017 49,000 $ 1.49 3.44 191,600 Exercisable, September 30, 2017 39,750 $ 1.53 3.41 $ 153,900 In connection with a private placement that took place on April 7, 2017, the Company issued warrants at a 1:1 ratio for shares purchased by investors. The warrants were valued using the Black Scholes valuation model. A summary of the Company’s warrant activity for the nine months ending September 30, 2017 is as follows: September 30, 2017 Volatility 76.66%-90.86 % Expected term (in years) 1 Risk-free interest rate 1.07% - 1.11 % Expected dividend yield None Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2016 - $ - - $ - Granted 10,040 30.00 1 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2017 10,040 $ 30.00 .55 $ - Exercisable, September 30, 2017 10,040 $ 30.00 .55 $ -	On January 5, 2013, the Company granted 96,000 options to a former director, 72,000 of which were forfeited in a subsequent period. The options have an exercise period of four years with an exercise price of $1.00. In the event that the former director ceases to serve on the Board of Directors for any reason, the Director is entitled to a pro-rata portion of the annual options. The options were valued at $43,151 using the Black Scholes Option Pricing Model with the following inputs: stock price on measurement date: $1.80; Exercise price: $1.00; Option term: 4 years; Computed volatility: 448%. On November 4, 2016, the Board of Directors authorized the exercise of stock options held by the former director to purchase 24,000 shares of common stock. On October 1, 2016 the Company granted 12,000 options to an employee of the Company as compensation for being appointed the US Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options vest monthly with 3,000 options fully vested as of December 31, 2016. The options were valued at $65,290 using the Black Sholes Option Pricing Model with the following inputs: stock price on measurement date: $5.80; Exercise price: $2.00; Option term: 4 years; Computed volatility: 159%. The Company expensed $16,636 as of December 31, 2016. A summary of the Company’s option activity during the year ended December 31, 2016 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2015 24,000 $ 1.00 1.02 $ - Granted 12,000 2.00 4.00 - Forfeited - - - - Exercised (24,000 ) 1.00 - - Expired - - - - Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 - Exercisable, December 31, 2016 3,000 $ 2.00 3.75 $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Notes to Financial Statements
NOTE 11 - SUBSEQUENT EVENTS	Purchase of Treasury Shares Effective October 2, 2017, the Company entered into to a stock purchase agreement dated September 30, 2017, whereby for consideration of $1,387 the Company purchased 138,689 shares of its common stock from a third party investor. The shares were transferred to the Company on October 17, 2017 and will be held in treasury. Reverse Stock Split On October 11, 2017, the Company authorized a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock. The reverse stock split was approved and filed in the state of Nevada, and reported on Form 8-K filed on October 11, 2017. On November 21, 2017 the reverse stock split was approved by FINRA and the financial statements have been retroactively restated to reflect the split. November 15, 2017 Securities Purchase Agreement On November 15, 2017, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain institutional investors (the “Buyers”) with which it had no prior relationship, pursuant to which the Company has agreed to issue for a purchase price of $3,000,000, $3,350,000 in aggregate principal amount of Senior Convertible Notes (the “Notes”) to the Buyers, convertible into 670,000 shares of the Company’s common stock, par value $.001 per share (the “Common Stock”) and warrants to purchase an aggregate of 536,000 shares of Common Stock (the “Warrants”.) The Notes provide that the Company will repay the principal amount of Notes in equal monthly installments beginning on January 1, 2018 and repeating on the first business day of each calendar month thereafter until the fourteenth month anniversary date of issuance (each a “Installment Date”), and, subject to the Blocker (as defined below), the Company shall pre-deliver up to 670,000 shares of Common Stock to the Buyers in connection therewith (the “Pre-Delivery Shares”). Eighty-five (85%) percent of any cash proceeds received by the Buyers from the sale of Pre-Delivery Shares shall be applied against the particular installment amount due on such Installment Date under the Note. No interest will accrue under the Notes unless and until an Event of Default (as defined) has occurred and is not cured. The Notes are convertible at any time by the Holder into shares of Common Stock at the rate of $5.00 per share, subject to full ratchet anti-dilution adjustment (the “Conversion Price”). Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the “VWAP”). The Notes are senior in right of payment to all existing and future indebtedness of the Company except Permitted Indebtedness (as defined in the Note), including $12 million of senior secured indebtedness of the Company and its subsidiaries under an existing senior loan agreement, plus defined amounts of purchase money indebtedness in connection with bona fide acquisitions. The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent. The Warrants have a five year term and are exercisable into a number of shares of Common Stock equal to approximately eighty (80%) percent of the number of shares of Common Stock the Buyers would receive if the Notes were fully converted upon the date of issuance of the Notes. The Warrants are exercisable at $7.50 per share (150% of the conversion price of the Notes) subject to full ratchet anti-dilution protection. The Warrants will be exercisable on a cashless basis if a registration statement is not effective covering the resale of the underlying Warrant Shares. Conversion of the Notes and exercise of the Warrants are each subject to a blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company’s issued and outstanding Common Stock (each, a “Blocker”). The Company is required to file, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the “Registration Rights Agreement”). As a condition to the closing of the Financing, each Buyer, severally, will be required to execute a leak-out agreement (each, a “Leak-Out Agreement”) restricting such Buyer’s sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer’s pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company’s Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company’s Common Stock for three (3) trading days is less than $0.15 per share, the Company may further restrict the Buyers from selling at less than $0.15 per share; provided that the portion of the Notes subject to redemption on each Installment Date shall thereafter double. Roth Capital Partners, LLC (“Roth”), as the Company’s exclusive placement agent, will receive a cash commission for this transaction equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months. Amendment of Trade Facility Agreement On November 16, 2017, SkyPharm signed an amended agreement with Synthesis Structured Commodity Trade Finance Limited that increased the maximum aggregate facility limit from €2,000,000 to €6,000,000. All other terms of the original agreement remain the same (see Note 8).	a) Subsequent Events through April 14, 2017 Employment Agreement On January 1, 2017 the Company entered into an agreement whereby the employee will be granted €1,000 per month and an annual retainer of 25,000 stock options as compensation for being appointed the International Finance Manager of the Company. The options have an exercise period of four years with an exercise price of $1.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options were valued using the Black Sholes Option Pricing Model at $195,307, which will be amortized over the year. Advisory Board Agreement On January 3, 2017 the Company determined to create an advisory board and appointed Mr. Orestes Varvitsiotes as its first member. Mr. Varvitsiotes is a registered broker dealer who is currently engaged with Aegis Capital Corp. In connection therewith, the Company entered into an Advisory Board Member Consulting Agreement, dated as of January 3, 2017 whereby an annual retainer of 12,000 stock options was granted as compensation for services. The options have an exercise period of five years with an exercise price of $2.00. In the event that he ceases to work for the Company for any reason, he will be entitled to a pro rata portion of the annual options. The options were valued using the Black Sholes Option Pricing Model at $94,830, which will be amortized over the year. Loan Facility Agreements On January 13, 2017, Synthesis Peer-To Peer-Income Fund (the “Loan Facility”) advanced the Company an additional $155,516 in funding, the agreement between the Loan Facility and the Company was modified on March 23, 2017 to include the additional funding. On March 16, 2017 and March 20, 2017, SkyPharm entered into loan agreements with the Synthesis Peer-To Peer-Income Fund (the “Bridge Loans”). The Bridge Loans provided to SkyPharm loans of $50,000 and $100,000, respectively. The Bridge Loans accrue interest at a rate of 10% per annum and are repayable on April 16, 2017 and April 20, 2017, respectively together with all other amounts then accrued and unpaid. On March 23, 2017, Sky Pharm S.A. (“Sky Pharm”), a wholly owned subsidiary of Company entered into an Amended and Restated Loan Facility Agreement (the “A&R Loan Facility”), guaranteed by Grigorios Siokas, the Company’s Chief Executive Officer, with Synthesis Peer-To Peer-Income Fund (the “Lender”). The A&R Loan Facility amends and restates certain provisions of the Loan Facility Agreement, dated as of August 4, 2016, by and among the same parties. The A&R Loan Facility provides an increased facility size of $2,664,960.22, of which Sky Pharm has borrowed the entire balance. Advances under the A&R Loan Facility continue to accrue interest at a rate of 10% per annum from the applicable date of each drawdown and require quarterly interest payments. The A&R Facility now permits prepayments at any time. The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018. The A&R Loan Facility is secured by a personal guaranty of Grigorios Siokas, which is secured by a pledge of 1,000,000 shares of common stock of the Company owned by Mr. Siokas (the “Pledged Shares”). The A&R Loan Facility was also amended to provide additional affirmative and negative covenants of Sky Pharm and the Guarantor during the term of loans remain outstanding, including, but not limited to, the consent of the Lender in connection with (i) the Company or any of its subsidiaries incurring any additional indebtedness; or (ii) in the event of any increase in the Company’s issued and outstanding shares of Common Stock, the Pledged Shares shall be increased to an amount equal to a minimum of ten percent (10%) of the issued and outstanding shares of the Company. On April 10, 2017, Decahedron Ltd. (“Decahedron”), a wholly owned subsidiary, as of February 9, 2017, of the Company entered into a Trade Finance Facility Agreement (the “Decahedron Facility”) with Synthesis Structured Commodity Trade Finance Limited (the “Lender”). The Decahedron Facility provides the following material terms: · The Lender will provide Decahedron a facility of up to €2,750,000 ($2,901,800) secured against Decahedron’s receivables from the sale of branded and generic pharmaceutical sales. · The total facility will be calculated as 95% of the agreed upon value of Decahedron’s receivables. · The term of the Decahedron Facility will be for 12 months. · The obligations of Decahedron are guaranteed by the Company pursuant to a Cross Guarantee and Indemnity Agreement. · The Lender has the right to make payments directly to Decahedron’s suppliers. · The following fees should be paid in connection with the Decahedron Facility: o 2% of the maximum principal amount as an origination fee. o A one percent (1%) monthly fee. The Company is in the process of obtaining the required consent from Synthesis Peer-To Peer-Income Fund in connection with certain negative covenants of the Company and Decahedron that restrict the Company and/or its subsidiaries from incurring any additional indebtedness or encumbering their assets. There can be no assurance such consent will be obtained. Letter of Intent with CC Pharma Gmbh On January 18, 2017 the Company signed a Letter of Intent (LOI) with the owners of CC Pharma who intended to sell all of their shares to the Company. According to the Letter of Intent, inter alia, the Parties agreed: · Parties shall negotiate a Share Purchase Agreement regarding the sale and transfer of CC Pharma shares to the Company. · Company shall be entitled to conduct due diligence with regard to financial, legal and tax matters and that the Parties shall cooperate in good faith to complete the due diligence process in due course. · The Parties will employ best efforts to achieve Closing of the Transaction by April 1, 2017. · Sellers grant to the Company the exclusive right to acquire their shares of CC Pharma Gmbh. This exclusive right expires on April 1, 2017. During this period the Sellers will not actively market or enter into negotiations with any other buyer. · Parties agreed that certain current managers of CC Pharma will remain managing directors of the Company at least until December 31, 2017. Parties will negotiate in good faith customary service agreements for the managing directors, whereby the Parties agree that the economic conditions of such new agreements shall be equal or more favorable for the managing directors compared to their current service agreements. Memoranda of Understanding- Stock Purchase Agreement – Completion/Closing of Acquisition On February 9, 2017 the Company and Decahedron consummated the transactions contemplated by the Decahedron SPA. Pursuant to the terms of the Decahedron SPA, the shareholders of Decahedron received an aggregate of 170,000 shares of common stock of the Company (the “Stock Consideration”), which were delivered at closing in exchange for all of the Ordinary Shares of Decahedron for the Stock Consideration. In accordance with the terms of the SPA, Mr. Lazarou remained as a director and officer of Decahedron with a salary of 10,000 GBP per month (approximately US $12,270). The Company consummated this transaction on February 10, 2017. On April 7, 2017, the Company issued the 170,000 shares to Decahedron. Consulting Agreement On March 1, 2017, the Company entered into a four-month consulting agreement with ArKo European Business & Services GmbH for consideration of 500 restricted shares of common stock to be issued during the period of the agreement. Convertible Promissory Note In a board meeting on April 10, 2017, the members of the Board of Directors authorized the Company to negotiate additional financing through a convertible note payable to Coastal Capital Partners (Black Forest Capital, LLC). The proposed terms contemplate an aggregate total proceeds received from Coastal Capital Partners will be $500,000 in three separate tranches. Interest will be 8% per annum and the conversion rate will be 70% of the average of the lowest five trading prices of shares traded within twenty trading days prior to the date of conversion. As of the date of filing, the Company has not received any funds and there has been no formal agreement between the Company and Coastal Capital Partners. No assurances can be made that the Company will consummate these transactions. b) Reverse Stock Split On October 11, 2017, the Company authorized a one-for-ten (1:10) reverse stock split whereby the Company decreased, by a ratio of one-for-ten (1:10) the number of issued and outstanding shares of Common Stock. The reverse stock split was approved and filed in the state of Nevada, and reported on Form 8-K filed on October 11, 2017. On November 21, 2017 the reverse stock split was approved by FINRA and the financial statements have been retroactively restated to reflect the split.

ORGANIZATION, NATURE OF BUSIN21

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Organization Nature Of Business And Going Concern Policies
Basis of Financial Statement Presentation	The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America.	The accompanying consolidated financial statements have been prepared in accordance with principles generally accepted in the United States of America.
Principles of Consolidation	Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd, SkyPharm S.A. and Decahedron Ltd. All significant intercompany balances and transactions have been eliminated.	Our consolidated accounts include our accounts and the accounts of our wholly-owned subsidiaries, Amplerissimo Ltd and SkyPharm S.A. All significant intercompany balances and transactions have been eliminated.
Reclassifications to Prior Period Financial Statements and Adjustments	Certain reclassifications have been made in the Company’s financial statements of the prior year to conform to the current year presentation. These reclassifications have no impact on previously reported net income.
Use of Estimates	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.	The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of September 30, 2017 and December 31, 2016, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. The Company also maintains bank accounts in the United Kingdom of Great Britain, dominated in Euros and Great Britain Pound (British Pounds Sterling).	For purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. As of December 31, 2016 and December 31, 2015, there were no cash equivalents. The Company maintains bank accounts in the United States denominated in U.S. Dollars and in the Republic of Cyprus, in Greece and in Bulgaria all of them denominated in Euros. For the year ended December 31, 2016, the amounts in these accounts were $3,143 and $19,876 (the Euro equivalent of which was €18,836). At December 31, 2015, the amounts in these accounts were $(190) and $7,808 (the Euro equivalent of which was €7,159).
Account Receivable	Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information.	Accounts receivable are stated at their net realizable value. The allowance for doubtful accounts against gross accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other currently available information.
Inventory	Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.	Inventory is stated at the lower of cost or market value using the weighted average method. Inventory consists primarily of finished goods and packaging materials, i.e. packaged pharmaceutical products and the wrappers and containers they are sold in. A periodic inventory system is maintained by 100% count. Inventory is replaced periodically to maintain the optimum stock on hand available for immediate shipment. We write-down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results.
Fixed Assets	Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5-7 years Office and computer equipment 3-5 years Depreciation expense was $10,831 and $6,956 for the nine months ended September 30, 2017 and 2016, respectively.	Fixed assets are stated at cost, less accumulated depreciation. Depreciation is provided on a straight-line basis over the useful lives (except for leasehold improvements which are depreciated over the lesser of the lease term or the useful life) of the assets as follows: Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years Depreciation expense was $9,448 and $5,416 for the years ended December 31, 2016 and December 31, 2015, respectively.
Intangible Assets	Intangible assets with definite useful lives are recorded on the basis of cost and are amortized on a straight-line basis over their estimated useful lives. The Company uses a useful life of 5 years for an import/export license. The Company evaluates the remaining useful life of intangible assets annually to determine whether events and circumstances warrant a revision to the remaining amortization period. If the estimate of the intangible asset’s remaining useful life is changed, the remaining carrying amount of the intangible asset will be amortized prospectively over that revised remaining useful life. At September 30, 2017, no revision to the remaining amortization period of the intangible assets was made. Amortization expense was $6,368 and $0 for the nine months ended September 30, 2017 and 2016, respectively.
Impairment of Long-Lived Assets	In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.	In accordance with ASC 360-10, Long-lived assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Goodwill and Intangibles	The Company periodically reviews the carrying value of intangible assets not subject to amortization, including goodwill, to determine whether impairment may exist. Goodwill and certain intangible assets are assessed annually, or when certain triggering events occur, for impairment using fair value measurement techniques. These events could include a significant change in the business climate, legal factors, a decline in operating performance, competition, sale or disposition of a significant portion of the business, or other factors. Specifically, goodwill impairment is determined using a two-step process. The first step of the goodwill impairment test is used to identify potential impairment by comparing the fair value of a reporting unit with its carrying amount, including goodwill. The Company uses level 3 inputs and a discounted cash flow methodology to estimate the fair value of a reporting unit. A discounted cash flow analysis requires one to make various judgmental assumptions including assumptions about future cash flows, growth rates, and discount rates. The assumptions about future cash flows and growth rates are based on the Company’s budget and long-term plans. Discount rate assumptions are based on an assessment of the risk inherent in the respective reporting units. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired and the second step of the impairment test is unnecessary. If the carrying amount of a reporting unit exceeds its fair value, the second step of the goodwill impairment test is performed to measure the amount of impairment loss, if any. The second step of the goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds the implied fair value of that goodwill, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined in the same manner as the amount of goodwill recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of the assets and liabilities of that unit (including any unrecognized intangible assets) as if the reporting unit had been acquired in a business combination and the fair value of the reporting unit was the purchase price paid to acquire the reporting unit. Prior to the acquisition of Decahedron, the Company had no record goodwill value. As a result of the acquisition of Decahedron, the Company tested and expensed 100% of the goodwill allocated to the acquisition costs, an amount equal to $1,949,884 for the period ending September 30, 2017.
Fair Value Measurement	The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company’s financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of September 30, 2017. Cash is considered to be highly liquid and easily tradable as of September 30, 2017 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.	The Company adopted FASB ASC 820-Fair Value Measurements and Disclosures, or ASC 820, for assets and liabilities measured at fair value on a recurring basis. ASC 820 establishes a common definition for fair value to be applied to existing generally accepted accounting principles that require the use of fair value measurements establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of ASC 820 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company did not have any Level 2 or Level 3 assets or liabilities as of December 31, 2016. Cash is considered to be highly liquid and easily tradable as of December 31, 2016 and therefore classified as Level 1 within our fair value hierarchy. In addition, FASB ASC 825-10-25 Fair Value Option, or ASC 825-10-25, was effective for January 1, 2008. ASC 825-10-25 expands opportunities to use fair value measurements in financial reporting and permits entities to choose to measure many financial instruments and certain other items at fair value. The Company did not elect the fair value options for any of its qualifying financial instruments.
Revenue Recognition	We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided.	We consider revenue recognizable when persuasive evidence of an arrangement exists, the price is fixed or determinable, goods or services have been delivered, and collectability is reasonably assured. These criteria are assumed to have been met if a customer orders an item, the goods or services have been shipped or delivered to the customer, and we have sufficient evidence of collectability, such a payment history with the customer. Revenue that is billed and received in advance such as recurring weekly or monthly services are initially deferred and recognized as revenue over the period the services are provided.
Stock-based Compensation	The Company records stock based compensation in accordance with ASC section 718, “Stock Compensation” and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 “Equity-Based Payments to Non-Employees”.	The Company records stock based compensation in accordance with ASC section 718, "Stock Compensation" and Staff Accounting Bulletin (SAB) No. 107 (SAB 107) issued by the SEC in March 2005 regarding its interpretation of ASC 718. ASC 718 requires the fair value of all stock-based employee compensation awarded to employees to be recorded as an expense over the related requisite service period. The Company values any employee or non-employee stock based compensation at fair value using the Black-Scholes Option Pricing Model. The Company accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 505-50 "Equity-Based Payments to Non-Employees".
Foreign Currency Translations and Transactions	Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders’ equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity’s local currency) are included in net earnings.	Assets and liabilities of all foreign operations are translated at year-end rates of exchange, and the statements of operations are translated at the average rates of exchange for the year. Gains or losses resulting from translating foreign currency financial statements are accumulated in a separate component of stockholders' equity until the entity is sold or substantially liquidated. Gains or losses from foreign currency transactions (transactions denominated in a currency other than the entity's local currency) are included in net earnings.
Income Taxes	The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus, Greece and the United Kingdom of England. The corporate income tax rate in Cyprus is 12.5%, 29% in Greece (tax losses are carried forward for five years effective January 1, 2013) and 20% in United Kingdom of England. Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At September 30, 2017 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management’s judgment, the position is not more-likely-then-not sustainable upon audit based on the position’s technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of September 30, 2017 the Company has no uncertain tax positions recorded in any jurisdiction where it is subject to income tax.	The Company accounts for income taxes under the asset and liability method, as required by the accounting standard for income taxes ASC 740. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, as well as net operating loss carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company is liable for income taxes in the Republic of Cyprus and Greece. The corporate income tax rate in Cyprus is 12.5% and 29% in Greece and tax losses are carried forward for five years effective January 1, 2013 (prior to 2013, losses were carried forward indefinitely). Losses may also be subject to limitation under certain rules regarding change of ownership. We regularly review deferred tax assets to assess their potential realization and establish a valuation allowance for portions of such assets to reduce the carrying value if we do not consider it to be more likely than not that the deferred tax assets will be realized. Our review includes evaluating both positive (e.g., sources of taxable income) and negative (e.g., recent historical losses) evidence that could impact the realizability of our deferred tax assets. At December 31, 2016 the Company has maintained a valuation allowance against all net deferred tax assets in each jurisdiction in which it is subject to income tax. We recognize the impact of an uncertain tax position in our financial statements if, in management's judgment, the position is not more-likely-then-not sustainable upon audit based on the position's technical merits. This involves the identification of potential uncertain tax positions, the evaluation of applicable tax laws and an assessment of whether a liability for an uncertain tax position is necessary. As of December 31, 2016 the Company has no uncertain tax positions recorded in any jurisdiction where it is subject to income tax.
Basic and Diluted Net Income (Loss) per Common Share	Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in periods with net income. Basic and diluted loss per share for each of the periods ended September 30, 2017 and 2016 is the same due to the anti-dilutive nature of potential common stock equivalents.	Basic and diluted net loss per share calculations are calculated on the basis of the weighted average number of common shares outstanding during the periods presented. The per share amounts include the dilutive effect of common stock equivalents in years with net income. Basic and diluted loss per share for each of the years ended December 31, 2015 and 2016 is the same due to the anti-dilutive nature of potential common stock equivalents.
Recent Accounting Pronouncements	In January 2017, the FASB issued ASU 2017-04, Intangibles – Goodwill and Other (Topic 350), which simplifies the measurement of goodwill by eliminating Step 2 from the current goodwill impairment test in the event that there is evidence of an impairment based on qualitative or quantitative assessments. ASU 2017-04 does not change how the goodwill impairment is identified, and the Company will continue to perform a qualitative assessment annually to determine whether the two step impairment test is required. Until the adoption, current accounting standards require the impairment loss to be recognized under Step 2 of the impairment test. This requires the Company to calculate the implied fair value of goodwill by assigning fair value to the reporting unit’s assets and liabilities as if the reporting unit has been acquired in a business combination, then subsequently subtracting the implied goodwill from the carrying amount of the goodwill. The new standard would require the Company to determine the fair value of the reporting unit and subtract the carrying value from the fair value of the reporting unit to determine if there is an impairment. ASU 2017-04 is effective for the Company for fiscal years after December 15, 2019, and early adoption is permitted. ASU 2017-04 is required to be adopted prospectively, and the adoption is effective for annual goodwill impairment tests performed in the year of adoption. The Company does not believe that the adoption of ASU No. 2017-4 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations In January 2017, the FASB issued ASU No. 2017-01, “Clarifying the Definition of a Business,” with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as an acquisition of assets or a business. ASU No. 2017-01 is effective for the Company’s fiscal year commencing on January 1, 2018. The effect of this guidance is to be applied prospectively and early adoption is permitted. The Company does not believe that the adoption of ASU No. 2017-01 will have a material effect on the Company’s consolidated financial position or the Company’s consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases,” which will require lessees to recognize assets and liabilities for the rights and obligations created by most leases on the balance sheet. The changes become effective for the Company’s fiscal year beginning July 1, 2019. Modified retrospective adoption for all leases existing at, or entered into after, the date of initial application, is required with an option to use certain transition relief. The Company expects this ASU will increase its current assets and current liabilities, but have no net material impact on its consolidated financial statements. In May 2014, the FASB issued ASU 2014-09--Revenue from Contracts with Customers (Topic 606). The guidance requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The FASB delayed the effective date to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. In addition, in March and April 2016, the FASB issued new guidance intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. Both amendments permit the use of either a retrospective or cumulative effect transition method and are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early application permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements.	In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which delays the effective date of the revenue standard issued in 2014, ASU 2014-09, Revenue from Contracts with Customers. In response to stakeholders' requests to defer the effective date of the guidance in ASU 2014-09 and in consideration of feedback received through extensive outreach with preparers, practitioners, and users of financial statements, the FASB proposed deferring the effective date of ASU 2014-09. Respondents to the proposal overwhelmingly supported a deferral. Respondents noted that providing sufficient time for implementation of the guidance in ASU 2014-09 is critical to its success. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes, which requires that an entity classify deferred tax assets and liabilities as noncurrent on the balance sheet. Prior to the issuance of the standard, deferred tax assets and liabilities were required to be separated into current and noncurrent amounts on the basis of the classification of the related asset or liability. This ASU is effective for the Company on April 1, 2017, with early adoption permitted. The adoption of ASU No. 2015-17 is not expected to have a material impact on the Company's condensed consolidated financial statements or related disclosures. Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company's financial statements.
Concentrations of Credit Risk		Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash investments and accounts receivable. The following tables show the number of the Company's clients which contributed 10% or more of revenue and accounts receivable, respectively: Year Ended December 31, Year Ended December 31, 2016 2015 Number of 10% clients 2 2 Percentage of total revenue 52.49 % 87.21 % Percentage of total AR 26.09 % 46.97 %

ORGANIZATION, NATURE OF BUSIN22

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Organization Nature Of Business And Going Concern Tables
Schedule of Calculation of Fixed Assets	Estimated Useful Life Furniture and fixtures 5-7 years Office and computer equipment 3-5 years	Estimated Useful Life Furniture and fixtures 5–7 years Office and computer equipment 3-5 years
Schedule of Concentrations of Credit Risk		Year Ended December 31, Year Ended December 31, 2016 2015 Number of 10% clients 2 2 Percentage of total revenue 52.49 % 87.21 % Percentage of total AR 26.09 % 46.97 %

ACQUISITION OF DECAHEDRON, LTD

ACQUISITION OF DECAHEDRON, LTD (Table)	9 Months Ended
	Sep. 30, 2017
Acquisition Of Decahedron Ltd Table
Unaudited allocation of purchase price	Preliminary Allocation as of February 10, Allocation Final 2017 Adjustments Allocation Current assets $ 6,537 $ - $ 6,537 Intangible assets 50,000 - 50,000 Other assets 305,400 (216,562 ) 88,838 Total assets acquired 361,937 (216,562 ) 145,375 Liabilities assumed: Debt 804,819 (188,560 ) 616,259 Total liabilities assumed 804,819 (188,560 ) 616,259 Net assets acquired (442,882 ) (28,002 ) (470,884 ) Consideration: Value of Common Stock Issued at Acquisition 1,479,000 - 1,479,000 Goodwill $ 1,921,882 $ 28,002 $ 1,949,884
Intangible assets	Amount Useful Life (Years) Licenses (a) $ 50,000 5 $ 50,000 -
Unaudited Supplemental Pro Forma Data	Nine Months Ended September 30, 2017 2016 Revenues $ 19,968,845 $ 5,007,806 Cost of revenues 18,356,228 4,672,794 Gross profit 1,612,617 335,012 Operating expenses 4,411,620 614,515 Operating loss (2,799,003 ) (279,503 ) Other income (expense) (524,952 ) (238,528 ) Net Loss $ (3,323,955 ) $ (518,031 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2016
Income Taxes Tables
Schedule of reconciliation of income tax expense	12/31/2016 12/31/2015 US Income before income taxes $ (592,288 ) $ (6,687,709 )) Taxes under statutory US tax rates $ (201,378 ) $ (2,273,821 )) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance $ 193,451 $ 159,457 Foreign tax rate differential $ 19,122 $ 2,126,593 Permanent differences $ 360 $ 183 State taxes $ (11,594 ) $ (12,412 )) Income tax expense $ (39 ) $ -
Net tax effects of temporary differences between the carrying amount of assets and liabilities	12/31/2016 12/31/2015 US Net operating loss carry forward $ 329,848 $ 247,025 Greece Net operating loss carry forward 176,443 77,319 Cyprus Net operating loss carry forward 11,052 11,018 Total deferred tax asset 517,343 335,362 Valuation allowance (517,343 ) (335,362 ) Deferred tax asset, net $ -- $ -

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share Tables
Computations of basic and diluted per share	12/31/2016 12/31/2015 Net (loss) income $ (601,002 ) $ (6,687,912 ) Weighted average common shares outstanding – basic 12,564,824 12,561,598 Option awards 8,074 20,687 Weighted average common shares outstanding - dilutive 12,564,824 12,561,598 Basic and Diluted (0.05 ) (0.53 )

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Stock Options And Warrants Tables
Schedule of option activity during the year	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 $ 74,400 Granted 37,000 1.32 3.58 150,800 Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2017 49,000 $ 1.49 3.44 191,600 Exercisable, September 30, 2017 39,750 $ 1.53 3.41 $ 153,900	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Options Shares Price Term Value Balance Outstanding, December 31, 2015 24,000 $ 1.00 1.02 $ - Granted 12,000 2.00 4.00 - Forfeited - - - - Exercised (24,000 ) 1.00 - - Expired - - - - Balance Outstanding, December 31, 2016 12,000 $ 2.00 3.75 - Exercisable, December 31, 2016 3,000 $ 2.00 3.75 $ -
Warrants were valued	September 30, 2017 Volatility 76.66%-90.86 % Expected term (in years) 1 Risk-free interest rate 1.07% - 1.11 % Expected dividend yield None
Warrants	Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Shares Price Term Value Balance Outstanding, December 31, 2016 - $ - - $ - Granted 10,040 30.00 1 - Forfeited - - - - Exercised - - - - Expired - - - - Balance Outstanding, September 30, 2017 10,040 $ 30.00 .55 $ - Exercisable, September 30, 2017 10,040 $ 30.00 .55 $ -

ORGANIZATION, NATURE OF BUSIN27

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Furniture and Fixtures [Member] | Minimum [Member]
Estimated Useful Life	5 years	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Estimated Useful Life	7 years	7 years
Office and computer equipment [Member] | Minimum [Member]
Estimated Useful Life	3 years	3 years
Office and computer equipment [Member] | Maximum [Member]
Estimated Useful Life	5 years	5 years

ORGANIZATION, NATURE OF BUSIN28

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details 1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization Nature Of Business And Going Concern Details 1
Number of 10% clients	2	2
Percentage of total revenue	52.49%	87.21%
Percentage of total AR	26.09%	46.97%

ORGANIZATION, NATURE OF BUSIN29

ORGANIZATION, NATURE OF BUSINESS AND GOING CONCERN (Details Narrative) - USD ($)	Oct. 11, 2017	Nov. 21, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Feb. 10, 2017	Sep. 27, 2013
State or country of incorporation					Nevada		Nevada
Date of incorporation					Jul. 21, 2009		Jul. 21, 2009
Net loss			$ (198,171)	$ (94,613)	$ (3,074,179)	$ (277,797)	$ (601,002)	$ (6,687,912)
Working capital deficit			(3,546,938)		(3,546,938)		2,234,720
Accumulated deficit			(4,076,398)		$ (4,076,398)		$ (1,002,219)	(401,217)
Description for periodic inventory system maintainance					A periodic inventory system is maintained by 100% count		A periodic inventory system is maintained by 100% count
Depreciation expense					$ 10,831	6,956	$ 9,448	5,416
Intangible asset, useful life					5 years
Amortization of intangible assets					$ 6,368	0
Impairment of goodwill					$ 1,949,884
Impairment of goodwill, percent					100.00%
Revenues			$ 9,546,951	$ 1,414,503	$ 19,775,398	$ 3,506,804	6,755,436	533,802
Change in revenues							$ 6,957,943
Amplerissimo Ltd [Member]
Equity ownership percentage										100.00%
Stock Purchase Agreement [Member] | Decahedron Ltd [Member]
Common stock shares reserved									170,000
Minimum [Member]
Client contribution percentage to revenue and accounts receivable							10.00%
Cyprus [Member]
Income tax rate					12.50%
Cash Equivalents							$ 19,876	7,808
United States [Member]
Cash Equivalents							$ 3,143	$ 190
Greece [Member]
Income tax rate					29.00%
United Kingdom of England [Member]
Income tax rate					20.00%
Subsequent Event [Member]
Reverse stock split	(1:10)	(1:10)

LOAN RECEIVABLE (Details Narrat

LOAN RECEIVABLE (Details Narrative) - Synthesis Management Limited [Member] - USD ($)	1 Months Ended
	Dec. 31, 2016	Feb. 28, 2016
Loan receivable		$ 131,900
Maturity date		Dec. 31, 2016
Amendment to maturity date	Dec. 31, 2017

ACQUISITION OF DECAHEDRON, LT31

ACQUISITION OF DECAHEDRON, LTD. (Details)	Sep. 30, 2017USD ($)
Intangible assets	$ 50,000
Decahedron Ltd [Member] | Preliminary Allocation as of February 10, 2017 [Member]
Current assets	6,537
Intangible assets	50,000
Other assets	305,400
Total assets acquired	361,937
Liabilities assumed:
Debt	804,819
Total liabilities assumed	804,819
Net assets acquired	(442,882)
Consideration:
Value of Common Stock Issued at Acquisition	1,479,000
Goodwill	1,921,882
Decahedron Ltd [Member] | Allocation Adjustments [Member]
Current assets
Intangible assets
Other assets	(216,562)
Total assets acquired	(216,562)
Liabilities assumed:
Debt	(188,560)
Total liabilities assumed	(188,560)
Net assets acquired	(28,002)
Consideration:
Value of Common Stock Issued at Acquisition
Goodwill	28,002
Decahedron Ltd [Member] | Final Allocation [Member]
Current assets	6,537
Intangible assets	50,000
Other assets	88,838
Total assets acquired	145,375
Liabilities assumed:
Debt	616,259
Total liabilities assumed	616,259
Net assets acquired	(470,884)
Consideration:
Value of Common Stock Issued at Acquisition	1,479,000
Goodwill	$ 1,949,884

ACQUISITION OF DECAHEDRON, LT32

ACQUISITION OF DECAHEDRON, LTD. (Details 1)	9 Months Ended
	Sep. 30, 2017USD ($)
Intangible assets	$ 50,000
Useful Life (Years)	5 years
Licenses [Member]
Intangible assets	$ 50,000	[1]
[1]	(a) U.K Pharmaceutical Wholesale Distribution License

ACQUISITION OF DECAHEDRON, LT33

ACQUISITION OF DECAHEDRON, LTD. (Details 2) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Cost of revenues	$ 8,772,138	$ 1,269,553	$ 18,156,795	$ 3,192,472	$ 6,154,396	$ 484,809
Gross profit	774,813	144,950	1,618,603	314,332	601,040	48,993
Operating expenses	758,365	175,919	4,383,623	473,249	803,547	491,452
Operating loss	$ 16,448	$ (30,969)	(2,765,020)	(158,917)	$ (202,507)	$ (442,459)
Decahedron Ltd [Member] | Proforma [Member]
Revenues			19,968,845	5,007,806
Cost of revenues			18,356,228	4,672,794
Gross profit			1,612,617	335,012
Operating expenses			4,411,620	614,515
Operating loss			(2,799,003)	(279,503)
Other income (expense)			(524,952)	(238,528)
Net Loss			$ (3,323,955)	$ (518,031)

ACQUISITION OF DECAHEDRON, LT34

ACQUISITION OF DECAHEDRON, LTD. (Details Narrative)	9 Months Ended
	Sep. 30, 2017USD ($)Integershares
Business acquisition, name of acquired entity	DECAHEDRON, LTD
Business acquisition outstanding percentage	100.00%
Number of businesses acquired | Integer	1
Business acquisition outstanding shares value	$ 1,479,000
Business acquisition outstanding shares in exchange | shares	1,700,000
Adjustment related to other assets and accounts payable	$ 28,002
Impairment of goodwill	$ 1,949,884
Impairment of goodwill, percent	100.00%
Acquisition [Member]
Revenues	$ 2,622,547
Net Loss	$ 255,672

PREPAID DEFERRED FINANCING CO35

PREPAID DEFERRED FINANCING COSTS (Details Narrative) - USD ($)	Sep. 30, 2017	Aug. 30, 2017	Feb. 28, 2016
Advanced for additional financing	$ 147,662
Synthesis Management Limited [Member]
Advanced for additional financing	$ 213,627	$ 213,627	$ 133,725

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes Details
Income before income taxes	$ (592,288)	$ (6,687,709)
Taxes under statutory US tax rates	(201,378)	(2,273,821)
Increase (decrease) in taxes resulting from:
Increase (decrease) in valuation allowance	193,451	159,457
Foreign tax rate differential	19,122	2,126,593
Permanent differences	360	183
State taxes	(11,594)	(12,412)
Income tax expense	$ (39)

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
United States [Member]
Net operating loss carry forward	$ 329,848	$ 247,025
Greece [Member]
Net operating loss carry forward	176,443	77,319
Cyprus [Member]
Net operating loss carry forward	11,052	11,018
Total deferred tax asset	517,343	335,362
Valuation allowance	(517,343)	(335,362)
Deferred tax asset, net

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Interest expense	$ 291,224	$ 53,794	$ 572,679	$ 103,803	$ 205,750	$ 86,898
Taxes payable	$ 1,313,030		1,313,030		1,080,590	$ 1,032,128
Income tax, penalties and interest expense			$ 63,724
Accrued expenses					86,409
United States [Member]
US net operating loss carry forwards					$ 329,848
Expiry					2,031
Greece [Member]
US net operating loss carry forwards					$ 176,443
Expiry					2,019
Cyprus [Member]
US net operating loss carry forwards					$ 11,052
Expiration period					5 years

CAPITAL STRUCTURE (Details Narr

CAPITAL STRUCTURE (Details Narrative) - USD ($)	Apr. 10, 2017	Apr. 07, 2017	Mar. 01, 2017	Nov. 04, 2016	Oct. 02, 2016	Jul. 21, 2017	May 25, 2017	May 18, 2017	May 16, 2017	Apr. 26, 2017	Apr. 28, 2015	Jan. 31, 2015	May 25, 2017	May 24, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015	Feb. 10, 2017
Common stock, shares issued																12,825,393		12,587,053	12,563,053
Common stock, shares, outstanding																12,825,393		12,587,053	12,563,053
Common stock shares authorized																300,000,000		300,000,000	300,000,000
Preferred stock shares authorized																100,000,000		100,000,000	100,000,000
Stock options granted																		12,000
Exercise price																		$ 1
Common stock vlaue																$ 12,825		$ 12,587	$ 12,563
Proceeds from stock options exercised																		24,000
Frequency of periodic payment												Monthly			Monthly
Stock-based compensation																$ 265,529		$ 16,636	28,352
Stock Option [Member] | Employee [Member]
Common stock shares reserved					16,636
Exercise period					4 years
Stock Option [Member] | Employee [Member] | On January 1, 2017 [Member]
Exercise period																4 years
Hellenic american securities [Member] | Consulting services [Member]
Common stock shares reserved											18,000
Consulting expense																			$ 28,352
Stock issued during period for services											4,500
Compensation periodic payment											$ 1,000
Frequency of periodic payment											Monthly
Former director [Member] | Stock Option [Member]
Shares issued				24,000
Proceeds from stock options exercised				$ 24,000
Private investor [Member] | Subscription Arrangement [Member]
Stock options granted	4,580								790	4,670
Price per share	$ 7					$ 5			$ 7	$ 7
Common stock value	$ 32,060					$ 21,500			$ 5,530	$ 32,690
Common Stock Shares Subscribed	4,580					4,300			790	4,670
Stock options granted fair value	$ 2,375								$ 130	$ 1,521
ArKo European Business & Services [Member] | Consulting agreement Four [Member]
Common stock, shares issued							20,000						20,000
Commencing agreement date							May 25, 2017
Consulting agreement period							20 months
Common stock vlaue							$ 154,000						$ 154,000
Price per share							$ 7.70						$ 7.70
Consultant charges							$ 32,874
ArKo European Business & Services [Member] | Consulting agreement Three [Member]
Common stock, shares issued								30,000
Commencing agreement date								May 8, 2017
Consulting agreement period								1 year
Common stock vlaue								$ 219,000
Monthly consultant charges								$ 5,000
ArKo European Business & Services [Member] | Consulting Agreement Two [Member]
Common stock, shares issued							2,000						2,000
Commencing agreement date													May 1, 2017
Consulting agreement period													5 months
Common stock vlaue							$ 14,400						$ 14,400
Price per share							$ 7.20						$ 7.20
ArKo European Business & Services [Member] | Consulting Agreement one [Member]
Common stock, shares issued														2,000
Commencing agreement date														May 1, 2017
Commencing terminating date														Jan. 1, 2018
Consulting agreement period														8 months
Common stock vlaue														$ 14,400
ArKo European Business & Services [Member] | Consulting Agreement [Member]
Restricted shares of common stock			500
Decahedron Ltd [Member] | Stock Purchase Agreement [Member]
Common stock shares reserved																				170,000
Potentially dilutive securities [Member] | Private Placement [Member]
Stock options granted		5,000
Common stock vlaue		$ 35,000
Stock options granted fair value		$ 35,000
Potentially dilutive securities [Member] | Employee [Member]
Stock options granted					12,000
Exercise period					4 years
Exercise price					$ 2
Stock options vested					3,000
Potentially dilutive securities [Member] | Employee [Member] | On January 3, 2017 [Member]
Stock options granted																12,000
Exercise period																5 years
Exercise price																$ 2
Potentially dilutive securities [Member] | Employee [Member] | On January 1, 2017 [Member]
Stock options granted																25,000
Exercise period																4 years
Exercise price																$ 1
Stock options vested																18,750
Potentially dilutive securities [Member] | Employee [Member] | On October 1, 2016 [Member]
Stock options granted																12,000
Exercise period																4 years
Exercise price																$ 2
Stock options vested																12,000
Equity issued in merger [Member] | Restricted Stock [Member] | Amplerissimo Ltd [Member] | Exchange agreement [Member]
Common stock, shares issued																10,000,000		100,000,000
Prior to merger [Member]
Common stock, shares issued																2,558,553		2,558,553
Post Merger [Member]
Common stock, shares issued																12,558,553		12,558,553
Common stock, shares, outstanding																12,558,553		12,558,553
Dimitrios Goulielmos [Member] | Restricted Stock [Member] | Amplerissimo Ltd [Member] | Exchange agreement [Member]
Restricted shares of common stock																10,000,000		10,000,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative)	Oct. 02, 2016USD ($)	Nov. 04, 2015USD ($)$ / sharesshares	Nov. 02, 2015USD ($)	Aug. 17, 2015USD ($)	Mar. 27, 2015USD ($)	Dec. 29, 2014USD ($)	Nov. 21, 2014USD ($)	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)shares	Dec. 31, 2014USD ($)	Sep. 30, 2017EUR (€)shares	Nov. 04, 2015EUR (€)	Jul. 22, 2009shares
Shares issued | shares								12,825,393		12,587,053	12,563,053		12,825,393
Repayment of related party debt								$ 232,051	$ 21,914	$ 15,300	$ 3,000
Officers and directors [Member]
Shares issued | shares															2,000,000
DOC Pharma S.A. [Member]
Prepaid balance								$ 410,991		$ 69
Description for prepaid balance percentage								over 10.3% of the Company’s total prepaid balance		Over 13% of the Company's total prepaid balance
Due to related party										$ 69	121,063
DOC Pharma S.A. [Member] | Loan agreement [Member]
Debt outstanding amount								$ 14,176
Short term debt, borrowing capacity			$ 12,662
Payment of miscellaneous bills			$ 12,000
Interest rate			2.00%
Maturity date			Oct. 31, 2016
Accrued interest			$ 308					612
DOC Pharma S.A. [Member] | Loan agreement [Member] | On November 1, 2015 [Member]
Short term debt, borrowing capacity								12,662
Payment of miscellaneous bills								$ 12,000
Interest rate								2.00%
Maturity date								Oct. 31, 2016
Grigorios Siokas [Member]
Prepaid balance										15,454
Due to related party	$ 5,276										10,906
Debt outstanding amount								$ 7,088		5,276
Repayment of related party debt										10,906
Short term debt, borrowing capacity								1,181
Maturity date	Oct. 1, 2017
Grigorios Siokas [Member] | On October 1, 2016 [Member]
Due to related party								$ 5,276
Maturity date								Oct. 1, 2017
Grigorios Siokas [Member] | Loan payable [Member]
Due to related party								$ 559,488		95,496
Debt outstanding amount								521,096		95,496
Repayment of related party debt								145,300
Ourania Matsouki [Member]
Due to related party								64,982		47,479	4,908
Debt outstanding amount								31,373		47,479
Repayment of related party debt								86,751		4,908
Konstantinos Vassilopoulos [Member]
Debt outstanding amount								369
Repayment of related party debt								9,810
Payment of miscellaneous bills										10,179
Dimitrios Goulielmos [Member]
Aggregate forgiveness of related party notes		$ 142,860									$ 362,859
Accrued interest expense										0
Debt instrument decrease accrued interest forgiveness		806
Gain on forgiveness of accrued salaries												$ 173,092
Due to related party				$ 50,000	$ 70,000	$ 3,000	$ 401,115			147,728				€ 200,000
Debt outstanding amount								102,182
Repayment of related party debt								63,200		$ 63,312
Interest rate				2.00%	2.00%		2.00%
Maturity date							May 11, 2015
Accrued interest | €													€ 0
Dimitrios Goulielmos [Member] | MediHelm S.A. [Member]
Due to related party								220,988
Dimitrios Goulielmos [Member] | Loan agreement [Member]
Due to related party						$ 100,000
Interest rate						2.00%
Maturity date						Jun. 30, 2015
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member]
Aggregate forgiveness of related party notes		$ 200,000
Sale of stock, number of shares issued | shares		95,000,000
Share price | $ / shares		$ 1
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | Other obligations [Member] | Minimum [Member]
Pledging for repayments of various liabilities under agreement		$ 5,000
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | Other obligations [Member] | Maximum [Member]
Pledging for repayments of various liabilities under agreement		10,000
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | The Amplerissimo tax liability [Member]
Pledging for repayments of various liabilities under agreement		817,811
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | Terzis [Member]
Pledging for repayments of various liabilities under agreement		2,400
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | Accounting fees [Member]
Pledging for repayments of various liabilities under agreement		3,000
Dimitrios Goulielmos [Member] | November 2015 Stock Purchase Agreement [Member] | Malone bailey [Member]
Pledging for repayments of various liabilities under agreement		$ 16,357
Mr. Siokas [Member]
Prepaid balance								$ 70,459

DEBT (Details Narrative)

DEBT (Details Narrative)	May 12, 2017USD ($)	May 05, 2017USD ($)	Apr. 10, 2017USD ($)	Mar. 16, 2017USD ($)	Aug. 04, 2016USD ($)shares	May 04, 2016USD ($)	Mar. 04, 2016USD ($)	Feb. 05, 2016USD ($)	Jan. 06, 2016USD ($)	Nov. 05, 2015USD ($)	Mar. 04, 2015USD ($)	Mar. 23, 2017USD ($)shares	Mar. 20, 2017USD ($)	Dec. 31, 2016USD ($)	Oct. 18, 2016USD ($)	May 24, 2016USD ($)	Apr. 22, 2016USD ($)	Apr. 19, 2016USD ($)	Nov. 16, 2015USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2017EUR (€)	Dec. 31, 2016USD ($)	Jul. 31, 2017USD ($)	Jan. 31, 2017USD ($)	Nov. 30, 2016USD ($)	Oct. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 13, 2016USD ($)	Dec. 31, 2015USD ($)
SkyPharm [Member]
Short term debt borrowing capacity	$ 2,282,200																			$ 6,162,736
Description for the repayment	The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables.
Amortization of debt discount																				34,881
Term of credit facility	12 months
Credit facilty origination fee, percentage	2.00%
Monthly credit fee, percentage	1.00%
Monthly fees																				201,661
Origination fees | €																					€ 104,338
Grigorios Siokas [Member]
Short term debt borrowing capacity																				1,181
Debt outstanding amount														$ 5,276						7,088		$ 5,276
Loan Agreement 4 [Member] | Panagiotis Drakopoulos [Member]
Short term debt borrowing capacity																			$ 43,624
Interest rate																			6.00%
Maturity date																			Nov. 15, 2016
Debt outstanding amount														42,208						35,439		42,208
Accrued interest														2,860						4,801		2,860
Repayment of debt																				11,813
Loan Agreement 5 [Member] | Panagiotis Drakopoulos [Member]
Short term debt borrowing capacity																													$ 32,718
Debt outstanding amount														17,938								17,938
Repayment of debt																				20,082		13,718
Loan Agreement 6 [Member]
Short term debt borrowing capacity								$ 21,104
Interest rate								6.00%
Accrued interest																				1,204
Loan Agreement 6 [Member] | Third party [Member]
Short term debt borrowing capacity																													$ 32,718
Repayment of debt																						32,718
Loan Agreement 7 [Member]
Short term debt borrowing capacity						$ 52,760	$ 52,760		$ 158,280
Interest rate							6.00%		1.00%
Maturity date							Mar. 4, 2017		Feb. 6, 2016
Accrued interest														483						886		483
Repayment of debt																						158,763
Loan Agreement 8 [Member]
Short term debt borrowing capacity								$ 21,104										$ 105,520
Interest rate								6.00%										6.00%
Maturity date																		Apr. 19, 2017
Debt outstanding amount														21,104								21,104
Accrued interest														1,150						3,662		1,150
Loan Agreement 9 [Member]
Short term debt borrowing capacity							$ 52,760										$ 40,098
Interest rate							6.00%										6.00%
Maturity date							Mar. 4, 2017										Apr. 22, 2017
Debt outstanding amount														52,760								52,760
Accrued interest														0						2,099		0
Loan Agreement 10 [Member]
Short term debt borrowing capacity																$ 52,760		$ 105,520
Interest rate																6.00%		6.00%
Maturity date																May 24, 2017		Apr. 19, 2017
Debt outstanding amount														105,520								105,520
Accrued interest														2,349						3,305		2,349
Repayment of debt																				59,065
Loan Agreement 11 [Member]
Short term debt borrowing capacity															$ 10,552		$ 40,098
Interest rate															10.00%		6.00%
Maturity date															Oct. 18, 2017		Apr. 22, 2017
Debt outstanding amount														40,098								40,098
Accrued interest														1,675						283		1,675
Repayment of debt																				11,813
Loan Agreement 12 [Member]
Short term debt borrowing capacity						$ 52,760
Interest rate						6.00%
Maturity date						May 4, 2017
Debt outstanding amount														52,760								52,760
Accrued interest														590								590
Loan Agreement 13 [Member]
Short term debt borrowing capacity																$ 52,760
Interest rate																6.00%
Maturity date																May 24, 2017
Debt outstanding amount														52,760								52,760
Accrued interest														1,928								1,928
Loan Agreement 14 [Member]
Short term debt borrowing capacity															$ 10,552
Interest rate															10.00%
Maturity date															Oct. 18, 2014
Debt outstanding amount														10,552								10,552
Accrued interest														214								214
Loan Agreement 3 [Member]
Short term debt borrowing capacity										$ 87,248
Proceeds from debt														76,342
Interest rate										5.00%
Maturity date										Nov. 5, 2016
Debt outstanding amount														68,588								68,588
Accrued interest														8,774								8,774
Repayment of debt																				64,972
Repayments of accounts receivable																				11,813
Loan facility agreement [Member] | SkyPharm [Member]
Short term debt borrowing capacity					$ 1,292,769
Interest rate					10.00%
Description for the repayment					The amounts owed under the Loan Facility shall be repayable upon the earlier of (i) three months following the demand of the lender; or (ii) August 31, 2018. No prepayment is permitted pursuant to the terms of the Loan Facility
Loan facility agreement [Member] | Grigorios Siokas [Member] | Synthesis facility agreement [Member]
Common stock shares reserved | shares					1,000,000
Amendment to loan facility agreement [Member] | SkyPharm [Member]
Short term debt borrowing capacity																												$ 1,533,020
Debt outstanding amount																												$ 240,251
Second amendment to loan facility agreement [Member] | SkyPharm [Member]
Short term debt borrowing capacity												$ 2,664,960		452,471								452,471	$ 342,327	$ 155,516	$ 250,000	$ 100,000	$ 174,000
Interest rate												10.00%
Maturity date												Aug. 4, 2016
Debt outstanding amount														2,509,444						3,007,287		2,509,444
Accrued interest														47,316						143,761		47,316
Description for the repayment												The amounts owed under the A&R Loan Facility shall be repayable upon the earlier of (i) seventy five days following the demand of the Lender; or (ii) August 31, 2018.
Common stock shares reserved | shares												1,000,000
Debt discount														126,624								126,624
Amortization of debt discount																				52,796		16,063
Bridge Loans [Member] | SkyPharm [Member]
Short term debt borrowing capacity		$ 34,745		$ 50,000									$ 118,130
Interest rate		10.00%		10.00%									10.00%
Maturity date		Sep. 30, 2017		Apr. 16, 2017									Apr. 20, 2017
Amended maturity date				May 16, 2017									May 20, 2017
Debt outstanding amount		$ 34,745		$ 50,000									$ 118,130
Accrued interest		$ 1,418		$ 4,518									$ 8,665
Loan Agreement 2 [Member]
Short term debt borrowing capacity										$ 21,812
Proceeds from debt														10,906
Interest rate										1.00%
Maturity date										Nov. 5, 2016
Debt outstanding amount														18,994						11,813		18,994
Accrued interest														437						514		$ 437
Repayment of debt														$ 2,110						9,450
Loan Agreement 1 [Member] | Angelo Drakopoulos [Member]
Short term debt borrowing capacity											$ 9,000
Repayments of outstanding bill											$ 9,000
Interest rate											8.00%
Maturity date											May 5, 2016
Debt outstanding amount											$ 9,000									9,000
Accrued interest											$ 814									$ 1,345
Decahedron [member] | SkyPharm [Member]
Short term debt borrowing capacity			$ 2,941,950
Description for the repayment			The total facility will be calculated as 95% of the agreed upon value of Decahedrons receivables
Term of credit facility			12 months
Credit facilty origination fee, percentage			2.00%
Monthly credit fee, percentage			1.00%
Subsequent Event [Member] | Second amendment to loan facility agreement [Member] | SkyPharm [Member]
Short term debt borrowing capacity												$ 2,664,960												$ 155,516

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)

Aug. 08, 2017

Oct. 02, 2016USD ($)shares

May 31, 2017EUR (€)

Oct. 25, 2016USD ($)

Jun. 30, 2016USD ($)

May 31, 2016USD ($)

Dec. 31, 2015USD ($)

Jan. 31, 2015USD ($)

Sep. 30, 2014USD ($)

Aug. 31, 2012USD ($)

Sep. 30, 2017USD ($)shares

Sep. 30, 2016USD ($)

Sep. 30, 2016USD ($)

Sep. 30, 2017USD ($)shares

Sep. 30, 2016USD ($)

Dec. 31, 2016USD ($)

Dec. 31, 2015USD ($)

Jun. 21, 2016USD ($)

Operating lease periodic payment

$ 730

$ 709

Frequency of periodic payment

Monthly

Monthly

Operating lease rental expense

$ 2,126

$ 2,126

$ 6,377

$ 2,834

$ 4,960

$ 12,053

Operating lease expiration date

Nov. 30, 2015

Decahedron [member]

Operating lease periodic payment

$ 2,415

Operating lease rental expense

19,580

Term of operating lease

1 year

Private Placement [Member]

Commitments and contingencies description

(1) a cash commission of 6% of the total gross proceeds for two named investors (2) a cash commission of 4% of total gross proceeds from five named investors and (3) excluding the five named investors in “(2)” a cash commission equal to 8% of the total gross proceeds from the Offering and the issuance to the Agent or its designees of warrants covering 8% of the shares of common stock issued or issuable by the Company in the Offering. Additionally, the Agent will receive a cash fee of 8% payable within 5 business days, but only in the event of, the receipt by the Company of any cash proceeds from the exercise of any warrants with an expiration equal to or less than 24 months sold in the Offering

Amplerissimo [Member]

Operating lease periodic payment

$ 122

Frequency of periodic payment

Monthly

Operating lease rental expense

368

368

1,105

1,103

1,462

1,462

Operating lease expiration date

Jul. 31, 2013

Operating lease renewal date

Jul. 31, 2015

SkyPharm [Member]

Operating lease periodic payment

€ 1,250

$ 4,802

Operating lease rental expense

$ 30,094

$ 25,961

84,710

64,127

$ 89,323

$ 60,614

Term of operating lease

6 years

SkyPharm [Member] | Additional space [Member]

Operating lease periodic payment

$ 2,021

$ 886

SkyPharm [Member] | First Floor [Member]

Operating lease periodic payment

$ 886

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member]

Operating lease periodic payment

$ 1,500

Common stock shares reserved | shares

200,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase III testing [Member]

Common stock shares reserved | shares

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Phase II testing [Member]

Common stock shares reserved | shares

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | conclusion of Phase I testing [Member]

Common stock shares reserved | shares

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | Conclusion of Preclinical Trials [Member]

Common stock shares reserved | shares

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member]

Operating lease periodic payment

$ 1,500

Common stock shares reserved | shares

200,000

200,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase III testing [Member]

Common stock shares reserved | shares

50,000

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Phase II testing [Member]

Common stock shares reserved | shares

50,000

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | conclusion of Phase I testing [Member]

Common stock shares reserved | shares

50,000

50,000

Anastasios Tsekas and Olga Parthenea Georgatsou [Member] | Intellectual property sale agreement [Member] | On October 1, 2016 [Member] | Conclusion of Preclinical Trials [Member]

Common stock shares reserved | shares

50,000

50,000

CC Pharma GmbH [Member]

Non-refundable fee

$ 454,800

Expense paid

$ 454,800

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Earnings Per Share Details
Net income (loss)	$ (198,171)	$ (94,613)	$ (3,074,179)	$ (277,797)	$ (601,002)	$ (6,687,912)
Weighted average common shares outstanding - basic					12,564,824	12,561,598
Option awards					80,741	206,873
Weighted average common shares outstanding - dilutive					12,564,824	12,561,598
Net income (loss) per share - basic and diluted	$ (0.02)	$ (0.01)	$ (0.24)	$ (0.02)	$ (0.05)	$ (0.53)

DEPOSIT ON PENDING ACQUISITION

DEPOSIT ON PENDING ACQUISITION (Details Narrative) - Amplerissimo Ltd [Member] - Share purchase agreement [Member] - USD ($)	1 Months Ended	12 Months Ended
	Aug. 19, 2014	Dec. 31, 2015
Price paid to the Seller		$ 6,041,924
Deposit on pending acquisition		0
Business acquisition purchase price payable to seller	$ 7,634,000
Business acquisition purchase price written off		$ 6,041,924
Business acquisition terms of agreement	The transaction contemplated that, at the closing (the "Closing"), Amplerissimo would have acquired from Seller all of the outstanding capital stock of B2IN for a purchase price of seven million euros (€7,000,000) or approximately $7,634,000

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Number of Shares
Outstanding, December 31, 2016	12,000	24,000
Granted		12,000
Forfeited
Expired		(24,000)
Outstanding, September 30, 2017		12,000
Exercisable at September 30, 2017		3,000
Weighted Average Exercise Price
Outstanding, December 31, 2016	$ 2	$ 1
Granted		2
Exercised		1
Outstanding, September 30, 2017		2
Exercisable at September 30, 2017		$ 2
Weighted Average Remaining Contractual Term
Outstanding, December 31, 2016		1 year 7 days
Granted		4 years
Forfeited		0 years
Exercised		0 years
Expired		0 years
Outstanding, September 30, 2017		3 years 9 months
Exercisable at September 30, 2017		3 years 9 months
Aggregate Intrinsic Value
Outstanding, December 31, 2016
Granted
Forfeited
Exercised
Expired
Outstanding, September 30, 2017
Exercisable at September 30, 2017
Options [Member]
Number of Shares
Outstanding, December 31, 2016	12,000
Granted	37,000
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	49,000	12,000
Exercisable at September 30, 2017	39,750
Weighted Average Exercise Price
Outstanding, December 31, 2016	$ 2
Granted	1.32
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	1.49	$ 2
Exercisable at September 30, 2017	$ 1.53
Weighted Average Remaining Contractual Term
Outstanding, December 31, 2016	3 years 9 months
Granted	3 years 6 months 29 days
Outstanding, September 30, 2017	3 years 5 months 9 days
Exercisable at September 30, 2017	3 years 4 months 28 days
Aggregate Intrinsic Value
Outstanding, December 31, 2016	$ 74,400
Granted	150,800
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	191,600	$ 74,400
Exercisable at September 30, 2017	$ 153,900

STOCK OPTIONS AND WARRANTS (D46

STOCK OPTIONS AND WARRANTS (Details 1)	9 Months Ended
	Sep. 30, 2017
Expected term (in years)	1 year
Expected dividend yield
Minimum [Member]
Volatility	76.66%
Risk-free interest rate	1.07%
Maximum [Member]
Volatility	90.86%
Risk-free interest rate	1.11%

STOCK OPTIONS AND WARRANTS (D47

STOCK OPTIONS AND WARRANTS (Details 2) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Number of Shares
Outstanding, December 31, 2016	12,000	24,000
Granted		12,000
Forfeited
Expired		24,000
Outstanding, September 30, 2017		12,000
Exercisable at September 30, 2017		3,000
Weighted Average Exercise Price
Outstanding, December 31, 2016	$ 2	$ 1
Granted		2
Exercised		1
Outstanding, September 30, 2017		2
Exercisable at September 30, 2017		$ 2
Weighted Average Remaining Contractual Term
Outstanding, December 31, 2016		1 year 7 days
Granted		4 years
Forfeited		0 years
Exercised		0 years
Expired		0 years
Outstanding, September 30, 2017		3 years 9 months
Exercisable at September 30, 2017		3 years 9 months
Aggregate Intrinsic Value
Outstanding, December 31, 2016
Granted
Forfeited
Exercised
Expired
Outstanding, September 30, 2017
Exercisable at September 30, 2017
Warrant [Member]
Number of Shares
Outstanding, December 31, 2016
Granted	10,040
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	10,040
Exercisable at September 30, 2017	10,040
Weighted Average Exercise Price
Outstanding, December 31, 2016
Granted	30
Forfeited
Exercised
Expired
Outstanding, September 30, 2017	30
Exercisable at September 30, 2017	$ 30
Weighted Average Remaining Contractual Term
Granted	1 year
Outstanding, September 30, 2017	6 months 18 days
Exercisable at September 30, 2017	6 months 18 days
Aggregate Intrinsic Value
Outstanding, December 31, 2016
Granted
Forfeited
Exercised
Expired
Outstanding, September 30, 2017
Exercisable at September 30, 2017

STOCK OPTIONS AND WARRANTS (D48

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	Oct. 02, 2016	Jan. 05, 2013	Sep. 30, 2017	Dec. 31, 2016
Stock options forfeited
Exercise price				$ 2
Investor [Member]
Warrants issued ratio description			1:1 ratio for shares
Stock Option [Member] | Aegis capital corp [Member]
Amortization expense			$ 70,796
Stock Option [Member] | Former director [Member]
Stock options granted		96,000
Stock options forfeited		72,000
Exercise period		4 years
Exercise price		$ 1
Stock options value		$ 43,151
Stock price		$ 1.80
Exercise price		$ 1
Option term		4 years
Volatility rate		448.00%
Common stock shares reserved		24,000
Stock Option [Member] | Employee [Member]
Stock options granted	12,000
Exercise period	4 years
Exercise price	$ 2
Stock options value	$ 65,290
Stock price	$ 5.80
Exercise price	$ 2
Option term	4 years
Volatility rate	159.00%
Common stock shares reserved	16,636
Stock options vested				12,000
Stock option periodic vesting	3,000
Frequency of periodic vesting	Monthly
Stock Option [Member] | Employee [Member] | January 1, 2017 [Member]
Stock price			$ 8.20
Exercise price			$ 1
Stock option periodic vesting			18,750
Share based compensation as annual retainer			25,000
Stock Option [Member] | Employee [Member] | On January 1, 2017 [Member]
Exercise period			4 years
Exercise price			$ 1
Stock options value			$ 195,307
Option term			4 years
Volatility rate			136.76%
Consideration under agreement			$ 1,000
Stock Option [Member] | Employee [Member] | On October 1, 2016 [Member]
Stock price			$ 5.80
Exercise price			$ 2
Stock Option [Member] | Mr. Orestes Varvitsiotes [member] | January 3, 2017 [Member]
Stock options granted			12,000
Exercise period			5 years
Exercise price			$ 2
Stock options value			$ 94,830
Stock price			$ 8.20
Exercise price			$ 2
Option term			5 years
Volatility rate			155.37%
Stock option periodic vesting			9,000
Stock Option [Member] | International Finance Manager [Member]
Amortization expense			$ 146,079
Stock Option [Member] | US Finance Manager [Member]
Amortization expense			$ 48,654	$ 16,636
Stock option periodic vesting			12,000
Stock Option [Member] | US Finance Manager [Member] | On October 1, 2016 [Member]
Stock options granted			12,000
Exercise period			4 years
Exercise price			$ 2
Stock options value			$ 65,290
Option term			4 years
Volatility rate			159.00%
Frequency of periodic vesting			Monthly

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 11, 2017	Oct. 02, 2017	Jan. 03, 2017	Jan. 02, 2017	Nov. 21, 2017	Nov. 15, 2017	Sep. 30, 2017	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value							$ 0.001	$ 0.001	$ 0.001
Exercise price								$ 2
Warrants [Member]
Exercise price							$ 30
Subsequent Event [Member]
Reverse stock split	(1:10)				(1:10)
Subsequent Event [Member] | Trade Facility Agreement [Member]
Credit facility maximum borrowing capacity						$ 2,000,000
Amendment to credit facility maximum borrowing capacity						$ 6,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Warrants [Member]
Common stock shares issuable upon conversion of debt/convertible securities						536,000
Maturity period						5 years
Convertible securities, terms of conversion feature						The Warrants have a five year term and are exercisable into a number of shares of Common Stock equal to approximately eighty (80%) percent of the number of shares of Common Stock the Buyers would receive if the Notes were fully converted upon the date of issuance of the Notes. The Warrants are exercisable at $7.50 per share (150% of the conversion price of the Notes) subject to full ratchet anti-dilution protection
Terms of Blocker Provision						Blocker provision which prevents any holder from converting or exercising, as applicable, the Notes or the Warrants, into shares of Common Stock if its beneficial ownership of the Common Stock would exceed 4.99% (subject to adjustment not to exceed 9.99%) of the Company's issued and outstanding Common Stock (each, a "Blocker")
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Senior Convertible Notes [Member]
Common stock shares issuable upon conversion of debt/convertible securities						670,000
Common stock, par value						$ 0.001
Repayment of convertible notes, description						The Notes provide that the Company will repay the principal amount of Notes in equal monthly installments beginning on January 1, 2018 and repeating on the first business day of each calendar month thereafter until the fourteenth month anniversary date of issuance
Event of default, description						The Company shall pre-deliver up to 6,700,00 shares of Common Stock to the Buyers in connection therewith (the 'Pre-Delivery Shares'). Eighty-five (85%) percent of any cash proceeds received by the Buyers from the sale of Pre-Delivery Shares shall be applied against the particular installment amount due on such Installment Date under the Note. No interest will accrue under the Notes unless and until an Event of Default (as defined) has occurred and is not cured
Conversion Price						$ 5
Event of default converstion price, description						Upon an Event of Default (as defined), the Buyers may convert at an alternative conversion price equal to the lower of the then applicable Conversion Price or seventy-five (75%) percent of the Volume-Weighted Average Price (as defined, the "VWAP")
Amount of senior secured indebtness						$ 12,000,000
Customary events of default, description						The Notes include customary Events of Default and provide that the Buyers may require the Company to redeem (regardless of whether the Event of Default has been cured) all or a portion of the Notes at a redemption premium of one hundred twenty-five (125%) percent, multiplied by the greater of the conversion rate and the then current market price. The Buyers may also require redemption of the Notes upon a Change of Control (as defined) at a premium of one hundred twenty-five (125%) percent
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Senior Convertible Note 1 [Member] | Institutional investors [Member]
Convertible notes payable, principal amount						$ 3,000,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | Senior Convertible Note 2 [Member] | Institutional investors [Member]
Convertible notes payable, principal amount						$ 3,350,000
Subsequent Event [Member] | Stock Purchase Agreement [Member] | Investor [Member]
Common stock shares acquired for consideration, value		$ 1,387
Common stock shares acquired for consideration, shares		138,689
Subsequent Event [Member] | Employment agreement [Member]
Consideration under agreement				$ 1,000
Exercise period				4 years
Exercise price				$ 1
Share based compensation				$ 195,307
Subsequent Event [Member] | Employment agreement [Member] | Stock Option [Member]
Share based compensation as annual retainer				25,000
Subsequent Event [Member] | Advisory board agreement [Member]
Exercise period			5 years
Exercise price			$ 2
Share based compensation			$ 94,830
Subsequent Event [Member] | Advisory board agreement [Member] | Stock Option [Member]
Share based compensation as annual retainer			12,000
Subsequent Event [Member] | Registration Rights Agreement [Member] | Securities Purchase Agreement [Member] | Warrants [Member]
Terms of agreement						The Company is required to file, within thirty (30) days of the Closing, a registration statement covering one hundred fifty (150%) percent of the maximum number of shares, underlying the Notes and Warrants pursuant to a registration rights agreement with the Buyers (the "Registration Rights Agreement")
Subsequent Event [Member] | Leak-out Agreement [Member] | Securities Purchase Agreement [Member] | Warrants [Member]
Terms of agreement						As a condition to the closing of the Financing, each Buyer, severally, will be required to execute a leak-out agreement (each, a "Leak-Out Agreement") restricting such Buyer's sale of shares of Common Stock underlying the Notes and Warrants on any Trading Day to not more than such Buyer's pro rata allocation of the greater of (x) sales with net proceeds of an aggregate of $20,000 or (y) twenty-five (25%) percent of the daily average trading volume of the Company's Common Stock. If after the closing of the Financing there is no Event of Default under the Notes, the VWAP of the Company's Common Stock for three (3) trading days is less than $0.15 per share, the Company may further restrict the Buyers from selling at less than $0.15 per share
Conditional proceeds from sale of common stock under the agreement						$ 20,000
Terms of commission to placement agent						Placement agent will receive a cash commission for this transaction equal to eight (8%) percent of the total gross proceeds of the offering and the issuance of five-year warrants to purchase eight (8%) percent of the shares of Common Stock issued or issuable in this offering (excluding shares of Common Stock issuable upon exercise of any Warrants issued to investors); however, will receive eight (8%) percent of any cash proceeds received from the exercise of any Warrants sold in the offering with an expiration equal to or less than twenty-four (24) months